[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 497
1. Camilot D, Pizzolitto S, DeMaglio G, Falconieri G: Intravesical botryoid adenocarcinoma of the prostate: report of an unusual growth pattern of prostatic carcinoma simulating a urinary bladder tumor. Ann Diagn Pathol; 2007 Dec;11(6):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravesical botryoid adenocarcinoma of the prostate: report of an unusual growth pattern of prostatic carcinoma simulating a urinary bladder tumor.
  • We report on 3 cases of prostatic carcinoma presenting with a predominant intravesical mass as to simulate clinically and macroscopically a primary tumor of the urinary bladder.
  • All patients had a medical history of a prostatic adenocarcinoma diagnosed between 5 and 7 years earlier and treated conservatively.
  • Because of instrumental evidence of a large urinary bladder mass, 2 patients underwent radical cystoprostatectomy based on suspicions for a primary urothelial tumor.
  • Either cystoscopic or direct specimen inspection revealed a lobulated, yellow-tan, and polypoid lesion with a broad implant in the trigonal bladder area in 1 case and a mixed, polypoid, and diffuse linitis plastica-like infiltration of the bladder wall in the other 2 cases.
  • Microscopically, sections of tumor mass as well as from the prostate featured a poorly differentiated adenocarcinoma compatible with the prostatic origin.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Recurrence, Local / pathology. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022125.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Azuma H, Yamamoto K, Inamoto T, Ibuki N, Kotake Y, Sakamoto T, Kiyama S, Ubai T, Takahara K, Segawa N, Narumi Y, Katsuoka Y: Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Am J Clin Oncol; 2009 Dec;32(6):592-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
  • OBJECTIVES: We tested the usefulness of balloon-occluded arterial infusion (BOAI) of anticancer agent (cisplatin/gemcitabine), concomitant with hemodialysis, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects, along with concurrent radiation [Osaka-Medical College (OMC)-regimen] in patients with locally advanced bladder cancer.
  • CONCLUSION: OMC-regimen, a new strategy for patients with locally-invasive bladder cancer, can be curative not only in patients for whom cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative treatment would otherwise seem the only option.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Balloon Occlusion. Cisplatin / administration & dosage. Cystectomy. Renal Dialysis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Choriocarcinoma / secondary. Choriocarcinoma / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Middle Aged. Muscle Neoplasms / secondary. Muscle Neoplasms / therapy. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593084.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Lerner SP, Shen S: Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer. Urol Oncol; 2008 Sep-Oct;26(5):481-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer.
  • The prostate is commonly involved by transitional cell carcinoma (TCC) in patients with bladder cancer.
  • Distinct patterns and extent of pTCC have been described and are associated with pathologic stage of the primary bladder tumor as well as prognosis.
  • Given the high incidence of pTCC and prostatic adenocarcinoma, radical cystoprostatectomy is the treatment of choice for loco-regional control for patients with T4a disease.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology


Advertisement
4. Kulkarni JN, Gorasia TK, Choudhary JP, Mahajan PP: Endometrioid carcinoma of the upper urinary tract. J Cancer Res Ther; 2010 Oct-Dec;6(4):578-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid carcinoma of the upper urinary tract.
  • Herein, we report a second case of endometrioid carcinoma of the upper urinary tract presenting 17 years after hysterectomy for high grade adenocarcinoma of ovary.
  • After complete work up, she underwent right radical nephro-ureterectomy with bladder cuff excision.
  • The histology showed endometrioid carcinoma of upper urinary tract without any evidence of endometriosis.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Urologic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21358108.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


5. Egevad L, Håkansson U, Grabe M, Ehrnstrom R: Urachal signet-cell adenocarcinoma. Scand J Urol Nephrol; 2009;43(1):88-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal signet-cell adenocarcinoma.
  • This report presents two cases of urachal signet-cell adenocarcinoma (USCA).
  • Cystoscopy showed tumours in the dome of the bladder and transurethral resection revealed signet ring cell carcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / metabolism. Urachus. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759168.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Keratin-20
  •  go-up   go-down


6. Smith AK, Hansel DE, Jones JS: Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma. Urology; 2008 May;71(5):915-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma.
  • OBJECTIVES: Cystitis cystica et glandularis (CCEG) and intestinal metaplasia (IM) have been suggested to represent precursors of bladder adenocarcinoma.
  • The relationship between these entities and the subsequent development of bladder carcinoma remains unclear.
  • METHODS: We retrospectively evaluated the association among florid CCEG, IM, and bladder carcinoma.
  • The records and imaging findings of patients with a pathologic diagnosis of florid CCEG and/or IM were reviewed for a concurrent or future diagnosis of bladder carcinoma or pelvic lipomatosis.
  • Of the 117 patients with CCEG, a subset was identified with concurrent mucinous adenocarcinoma (n = 1; <1%), squamous cell carcinoma (n = 4; 3%), or urothelial carcinoma (n = 34; 29%) at diagnosis.
  • Pure IM was identified concurrently with adenocarcinoma in 2 (10%), urothelial carcinoma in 4 (21%), and urothelial carcinoma with glandular differentiation in 1 (5%) of 19 patients.
  • CONCLUSIONS: Both florid CCEG and IM can be identified in benign bladder specimens or in conjunction with bladder carcinoma.
  • Although IM can be associated with a concurrent diagnosis of carcinoma, we found no evidence that it increases the future risk of malignancy and our findings do not support a recommendation for surveillance cystoscopy in such patients.
  • [MeSH-major] Cystitis / complications. Intestines / pathology. Precancerous Conditions / pathology. Urinary Bladder Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455631.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, Vora KC: Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol; 2006 Aug 20;24(24):3967-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.
  • PURPOSE: Radical cystectomy and pelvic lymphadenectomy (PLND) remains the standard treatment for localized and regionally advanced invasive bladder cancers.
  • We have constructed an international bladder cancer database from centers of excellence in the management of bladder cancer consisting of patients treated with radical cystectomy and PLND.
  • PATIENTS AND METHODS: Institutional radical cystectomy databases containing detailed information on bladder cancer patients were obtained from 12 centers of excellence worldwide.
  • RESULTS: The final nomogram included information on patient age, sex, time from diagnosis to surgery, pathologic tumor stage and grade, tumor histologic subtype, and regional lymph node status.
  • The predictive accuracy of the constructed international nomogram (concordance index, 0.75) was significantly better than standard American Joint Committee on Cancer TNM (concordance index, 0.68; P < .001) or standard pathologic subgroupings (concordance index, 0.62; P < .001).
  • CONCLUSION: We have developed an international bladder cancer nomogram predicting recurrence risk after radical cystectomy for bladder cancer.
  • The nomogram outperformed prognostic models that use standard pathologic subgroupings and should improve our ability to provide accurate risk assessments to patients after the surgical management of bladder cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Cystectomy. Nomograms. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Aug 20;24(24):3819-20 [16864852.001]
  • [ErratumIn] J Clin Oncol. 2007 Apr 10;25(11):1457
  • (PMID = 16864855.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


8. Sterk P, Shekarriz B, Günter S, Nolde J, Keller R, Bruch HP, Shekarriz H: Voiding and sexual dysfunction after deep rectal resection and total mesorectal excision: prospective study on 52 patients. Int J Colorectal Dis; 2005 Sep;20(5):423-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Postoperatively, we sought first to determine the frequency of a urinary or sexual dysfunction, secondly whether there is a time-dependent change of a dysfunction and thirdly whether there is a relationship between postoperative urological dysfunction and the patient's age.
  • RESULTS: Urological dysfunction: Preoperatively, 49 of the 52 patients had a completely normal bladder function and three patients had post void residual >100 ml.
  • Postoperatively, 12 of the 49 patients with normal preoperatively urinary function had voiding dysfunction, but only four male patients had residual urine in the third postoperative month.
  • Therefore, in about 90% of the patients, postoperative bladder function became normal and only 10% suffered from vesical denervation after 6 months.
  • We could not determine a relationship between the degree of bladder dysfunction and the patient's age due to a relatively small patient cohort in this study.
  • Eleven men specified a limited erection, but all had occasional sexual intercourse.
  • Although it is likely that the potency may diminish with advanced age, the incidence of impotence was not higher in the older patients of our study.
  • Of patients with postoperative bladder dysfunction, 90% improved within 6 months after surgery and only 10% continued to have bladder dysfunction beyond 6 months, indicating irreversible nerve damage.
  • [MeSH-major] Adenocarcinoma / physiopathology. Adenocarcinoma / surgery. Coitus. Digestive System Surgical Procedures / adverse effects. Rectal Neoplasms / physiopathology. Rectal Neoplasms / surgery. Urination

  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chirurg. 1989 Apr;60(4):228-34 [2721301.001]
  • [Cites] Br J Surg. 1983 Aug;70(8):460-2 [6871635.001]
  • [Cites] Urologe A. 1984 Nov;23(6):324-8 [6542708.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1988;114:5-19 [3201169.001]
  • [Cites] Br J Urol. 1995 Dec;76(6):752-6 [8535720.001]
  • [Cites] Br J Surg. 1998 Jan;85(1):92-7 [9462393.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10):1140-5 [8831531.001]
  • [Cites] J Am Coll Surg. 1996 Jun;182(6):495-502 [8646349.001]
  • [Cites] Urol Int. 1991;46(3):259-65 [1926639.001]
  • [Cites] Urol Int. 1985;40(1):60-4 [3976090.001]
  • [Cites] Langenbecks Arch Surg. 1999 Apr;384(2):167-75 [10328170.001]
  • [Cites] Ann Surg. 1980 Jan;191(1):81-6 [7352782.001]
  • [Cites] Ann Chir Gynaecol. 1988;77(2):51-6 [3232948.001]
  • [Cites] Dis Colon Rectum. 1994 Feb;37(2 Suppl):S42-6 [8313791.001]
  • (PMID = 15846498.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Ahmad NA, Memon A, Hussainy A: Abdominoperineal excision of male lower urinary tract for synchronous adenocarcinoma of urethra and urinary bladder. Urology; 2005 Mar;65(3):591
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominoperineal excision of male lower urinary tract for synchronous adenocarcinoma of urethra and urinary bladder.
  • Urethral adenocarcinoma is the least common histologic subtype of a rare primary carcinoma of the male urethra.
  • This report is of a 40-year-old morbidly obese man with synchronous adenocarcinoma of the bulbar urethra and bladder, treated surgically by en bloc abdominoperineal penoprostatocystectomy.
  • Synchronous occurrence of adenocarcinoma of the urethra and bladder has not been previously reported.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasms, Multiple Primary / surgery. Urethral Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780385.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


10. Rozet F, Lesur G, Cathelineau X, Barret E, Smyth G, Soon S, Vallancien G: Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol; 2008 Jun;179(6):2170-4; discussion 2174-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Prostate sparing cystectomy provides an alternative therapeutic option in highly selected patients with invasive bladder cancer who wish to avoid the significant functional side effects of traditional surgery.
  • Concern exists regarding the oncological safety of this technique especially with regard to the presence of prostatic urothelial cancer and incidental prostate adenocarcinoma.
  • Of 6 patients found to have prostate adenocarcinoma in transurethral prostate resection specimens 1 was treated with high intensity focused ultrasound and 5 were followed with active surveillance, 2 of whom later died of bladder cancer.
  • With appropriate screening the risk of a clinically significant prostate cancer appears to be low.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423740.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Kondo T: Bile duct adenocarcinoma with minor micropapillary component: a case report. Cases J; 2009;2(1):51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile duct adenocarcinoma with minor micropapillary component: a case report.
  • This histologic pattern has been described in various organs, including the breast, lung, urinary bladder, ovary, stomach, pancreas, and major salivary glands.
  • Here a case of bile duct adenocarcinoma with minor micropapillary component is described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2008 Aug;53(8):2287-9 [18224441.001]
  • [Cites] Pancreas. 2007 Aug;35(2):190-2 [17632330.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):809-15 [16784979.001]
  • [Cites] Mod Pathol. 2005 Nov;18(11):1504-11 [16007065.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1224-32 [7977945.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):319-26 [15104294.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • (PMID = 19144165.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2639564
  •  go-up   go-down


12. Nishio R, Furuya Y, Akashi T, Okumura A, Fuse H: Primary adenocarcinoma of the appendix invading the urinary bladder. Int Urol Nephrol; 2006;38(3-4):481-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the appendix invading the urinary bladder.
  • We report a case of adenocarcinoma of the appendix invading the urinary bladder in a 75-year-old man.
  • Although cystoscopic examination and computed tomography suggested a primary or secondary bladder tumor, repeated transurethral bladder biopsy could not confirm the neoplasm.
  • At operation a primary neoplasm of the appendix invading the bladder was discovered and en bloc resection of the urinary bladder with the adherent cecum followed by an ileocolonic anastomosis and ureterocutaneostomy was performed.
  • [MeSH-major] Adenocarcinoma / pathology. Appendiceal Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Urol. 1996 Aug;78(2):305-6 [8813936.001]
  • [Cites] J Urol. 1995 Apr;153(4):1220-1 [7869505.001]
  • [Cites] Cancer. 1976 May;37(5):2493-510 [1260730.001]
  • [Cites] Urol Int. 1997;58(2):124-7 [9096277.001]
  • [Cites] Int J Urol. 2001 Apr;8(4):196-8 [11260355.001]
  • [Cites] Dis Colon Rectum. 1985 Jun;28(6):457-9 [4006640.001]
  • [Cites] Hinyokika Kiyo. 2002 Jun;48(6):351-4 [12166235.001]
  • (PMID = 17160444.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


13. Wright JL, Porter MP, Li CI, Lange PH, Lin DW: Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer; 2006 Aug 15;107(4):721-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder.
  • BACKGROUND: Primary adenocarcinomas of the bladder and urachus are rare malignancies, and knowledge of the patient demographics, pathologic characteristics, and survival associated with these tumors is poor.
  • The current study compares disease-specific characteristics and survival associated with urachal and nonurachal primary bladder adenocarcinomas.
  • METHODS: Incident cases of urachal and nonurachal primary adenocarcinomas of the bladder were identified from the Surveillance, Epidemiology, and End Results (SEER) Program.
  • Demographic and pathologic characteristics at the time of diagnosis were compared.
  • Risks of mortality among urachal and nonurachal primary adenocarcinomas of the bladder were compared using multivariate Cox regression.
  • RESULTS: A total of 151 urachal and 1374 nonurachal adenocarcinomas of the bladder patients were identified.
  • Compared to those with nonurachal tumors, patients with urachal adenocarcinoma were more likely to be younger (median age, 56 vs. 69 years, P <.0001) and female (45% vs. 36%, P = .02).
  • CONCLUSIONS. Urachal adenocarcinomas represent 10% of all primary adenocarcinomas of the bladder.
  • [MeSH-major] Adenocarcinoma / mortality. Urachus. Urinary Bladder Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826584.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Wang XH, Luo X, Chen SQ: [Impact of preservation of distal prostatic capsula and seminal vesicle on functions of orthotopic ideal neobladder and erectile function of bladder cancer patients]. Ai Zheng; 2008 Jan;27(1):62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of preservation of distal prostatic capsula and seminal vesicle on functions of orthotopic ideal neobladder and erectile function of bladder cancer patients].
  • BACKGROUND & OBJECTIVE: Radical cystectomy is the main treatment for invasive bladder cancer.
  • Using ileal neobladder to reconstruct the low urinary tract is commonly applied as urine diversion in recent years.
  • This study was to assess the impact of preservation of distal prostatic capsula and seminal vesicle during modified radical cystectomy on the functions of orthotopic ideal neobladder and erectile function of bladder cancer patients.
  • METHODS: Clinical data of 36 bladder cancer patients, treated from Jan.
  • At 6 months after operation, the differences in the capacity of the neobladder [(385+/-68) mL vs. (388+/-71) mL] and maximal filling pressure [(24+/-16) cmH2O vs. (25+/-15) cmH2O] between modified cystectomy group and classical cystectomy group were not significant (P>0.05); while the differences in maximal urine flow rate (Qmax) [(18+/-5) mL/s vs. (14+/-7) mL/s], residual urine volume [(35+/-16) mL vs. (97+/-35) mL], the occurrence of complete urinary continence [(24/27) vs. (3/9)], nocturnal incontinence [(3/27) vs. (6/9)], anastomotic stenosis [(4/27) vs. (3/9)], and erectile function preservation [(19/23) vs. (3/7)] between the 2 groups were significant (P<0.05).
  • [MeSH-major] Carcinoma, Transitional Cell. Cystectomy / methods. Penile Erection / physiology. Urinary Bladder Neoplasms. Urinary Diversion
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / physiopathology. Adenocarcinoma / surgery. Adult. Aged. Follow-Up Studies. Humans. Male. Middle Aged. Prostate. Seminal Vesicles. Urinary Reservoirs, Continent / physiology. Urination / physiology


15. Nassar OA: Modified le bag pouch after radical cystectomy: continence, urodynamic results and morbidity. J Egypt Natl Canc Inst; 2010 Mar;22(1):29-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To revaluate ileocolonic pouch for orthotopic neobladder reconstruction, a cohort of patients with bladder cancer was selected to undergo radical cystectomy and modified Le Bag pouch.
  • PATIENTS AND METHODS: A total of 37 patients including 16 females with T2-3 bladder cancer (19 transitional, 15 squamous and 3 adenocarcinoma) were treated by radical cystectomy and totally detubularized ileocolic neobladder.
  • Urinary leakage was the most frequent early complication (10.8%).
  • Late complications were urinary tract infection (13.5%), metabolic acidosis (13.5%) and reflux (10.8%).
  • Pouch over distension (5.4%) was consistent with bladder neck obstruction.
  • KEY WORDS: Continent urinary diversion - Orthotopic neobladder - Ileo colonic pouch - Modified Le Bag pouch.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21503004.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


16. Kurosaka S, Irie A, Mizoguchi H, Okuno N, Iwabuchi K, Baba S: Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy. Int J Clin Oncol; 2005 Oct;10(5):362-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy.
  • The tumor seemed to have arisen from the bladder or urethra, and bilateral iliac lymphadenopathy was seen.
  • Histopathological examination of the biopsy specimens showed clear-cell adenocarcinoma.
  • Macroscopically, the tumor had arisen from the trigone of the bladder, and histopathological examination of the tumor revealed adenocarcinoma exhibiting solid clear cells with glandular and papillary patterns.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2002 Aug;9(8):467-9 [12225345.001]
  • [Cites] Urol Int. 2003;71(2):228-30 [12890970.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(1):13-6 [8750509.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):39-48 [11121861.001]
  • [Cites] Mod Pathol. 1993 Mar;6(2):225-8 [8483895.001]
  • [Cites] J Urol. 1968 Oct;100(4):466-9 [5677385.001]
  • [Cites] Histopathology. 1990 Jun;16(6):601-4 [2376401.001]
  • [Cites] Urology. 1984 Mar;23(3):303-4 [6199882.001]
  • [Cites] J Urol. 1990 Jan;143(1):122-5 [2294240.001]
  • (PMID = 16247666.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Mai KT, Nguyen B: Urothelial carcinoma and prostatic adenocarcinoma presenting as collision tumors. Can J Urol; 2009 Oct;16(5):4850-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma and prostatic adenocarcinoma presenting as collision tumors.
  • Urothelial carcinoma (UC) and prostatic adenocarcinoma (PAC) commonly occur in elderly patients and share common carcinogenic factors that could be identified in the urine.
  • Simultaneous occurrence of PAC and UC in the prostate is not uncommon; however, urinary bladder location of both lesions has not yet been reported.
  • Furthermore, invasion into the urinary bladder wall by a PAC can also pose a diagnostic challenge with UC and other primary urinary bladder tumors.
  • We report three patients presenting with UC and PAC within the urinary bladder.
  • All patients were diagnosed with high grade PAC and either had simultaneous at the initial diagnosis or developed UC during the follow up for PAC.
  • In conclusion, awareness of this association is important in making the correct diagnosis, especially when dealing with urinary bladder biopsy material.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Biopsy. Combined Modality Therapy. Cystoscopy. Diagnosis, Differential. Fatal Outcome. Humans. Male


18. Kunze E, Krassenkova I, Fayyazi A: Tumor-associated neoexpression of the pS2 peptide and MUC5AC mucin in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder. Histol Histopathol; 2008 05;23(5):539-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated neoexpression of the pS2 peptide and MUC5AC mucin in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder.
  • To gain more detailed insight into the histogenesis of primary nonurachal adenocarcinomas and signet ring cell carcinomas of the urinary bladder, we analyzed by immunohistochemistry the expression of a broad panel of proteins, associated with cell differentiation (pS2 peptide, MUC5AC, MUC6, spasmolytic polypeptide, cyclooxygenases-1 and -2, caveolin-1), and of various novel known or candidate tumor suppressors (14-3-3 sigma, SYK, PTEN, maspin).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Signet Ring Cell / metabolism. Mucins / metabolism. Tumor Suppressor Proteins / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Fluorescent Antibody Technique, Indirect. Humans. Mucin 5AC. Neoplasm Proteins / metabolism. Trefoil Factor-1. Urinary Bladder / anatomy & histology. Urinary Bladder / metabolism. Urothelium / metabolism. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283638.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 0 / Neoplasm Proteins; 0 / TFF1 protein, human; 0 / Trefoil Factor-1; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


19. Spiess PE, Correa JJ: Robotic assisted laparoscopic partial cystectomy and urachal resection for urachal adenocarcinoma. Int Braz J Urol; 2009 Sep-Oct;35(5):609
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic assisted laparoscopic partial cystectomy and urachal resection for urachal adenocarcinoma.
  • A case of robotic assisted partial cystectomy and urachal resection for urachal adenocarcinoma is presented.
  • METHODS: A 55 years old African American male presented with hematuria and mucosuria, cystoscopy demonstrated a tumor involving the dome of the bladder.
  • Transurethral biopsy confirmed a urachal adenocarcinoma.
  • Preoperative abdominal/pelvic CT imaging revealed an enhancing mass extending from the inferior level of the umbilicus to the dome of the bladder.
  • The robotic assisted laparoscopic dissection was started at the level of the umbilicus, dissecting lateral to the right and left medial umbilical ligaments up until the dome of the bladder.
  • A simultaneous cystoscopy with transillumination to define the bladder boundaries of this mass, with robotic assisted laparoscopic opening of the bladder, with the entire mass (including bladder component) excised and sent for frozen pathology for margin evaluation.
  • After specimen extraction, the bladder was closed in two layers.
  • RESULTS: Final pathology reported a pT2N0Mx adenocarcinoma with negative margins and negative pelvic lymph nodes.
  • A cystogram perfomed on postoperative day 7 revealed a good bladder capacity (350 cc) and no leakage was identified.
  • CONCLUSIONS: Robotic assisted partial cystectomy and urachal resection for urachal adenocarcinoma of the bladder is feasible even in challenging cases.
  • [MeSH-major] Adenocarcinoma / surgery. Urachus / surgery. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860941.001).
  • [ISSN] 1677-6119
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Video-Audio Media
  • [Publication-country] Brazil
  •  go-up   go-down


20. Parikh B, Trivedi P, Ohri A, Shukla K, Desai S: Primary mucinous carcinoma of urachus--a case report. Indian J Pathol Microbiol; 2006 Jul;49(3):409-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Urachus. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001902.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


21. Pouessel D, Huguet H, Iborra F, Rebillard X, Ayuso D, Becht C, Culine S: A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer. Anticancer Res; 2010 Nov;30(11):4711-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
  • AIM: To assess the safety and to obtain preliminary data on the efficacy of the three-drug combination chemotherapy with gemcitabine, oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
  • PATIENTS AND METHODS: Patients with metastatic or locally unresectable advanced bladder cancer who had received either no or one previous systemic chemotherapy regimen were eligible.
  • Further clinical trials are not recommended.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115929.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


22. Trabelsi A, Ali AB, Yacoub-Abid LB, Stita W, Mokni M, Korbi S: Primary invasive micropapillary carcinoma of the colon: case report and review of the literature. Pathologica; 2008 Oct;100(5):428-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been reported in breast, urinary bladder, lung and the parotid gland, but very rarely in the colon.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Papillary / pathology. Liver Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Sigmoid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253607.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Neoplasm Proteins
  • [Number-of-references] 7
  •  go-up   go-down


23. Jouyaux F, De Crevoisier R, Manens JP, Bellec J, Cazoulat G, Haigron P, Chira C, Le Prisé E, Lafond C: [High dose for prostate irradiation with image guided radiotherapy: contribution of intensity modulation arctherapy]. Cancer Radiother; 2010 Dec;14(8):679-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Haute dose dans la prostate par radiothérapie guidée par l'image: apport de l'arcthérapie avec modulation d'intensité du faisceau.
  • PURPOSE: To compare two Intensity Modulated Radiation Therapy (IMRT) techniques for prostate cancer: the Volumetric Modulated Arc Therapy (VMAT) and the "Step and Shoot" technique (S&S).
  • RESULTS: VMAT, compared to S&S, offered: an increase of the PTV2s (prostate) volume receiving 77 to 80 Gy and a decrease of V(82) and V(83); a decrease of V(4) to V(6), V(16) to V(23), and V(69) to V(73) for the rectal wall; a decrease of V(25) for the bladder wall; a decrease of V(21) to V(43) for the femoral heads; a decrease of V(26) to V(44) and V(72) to V(80) but an increase of V(1) to V(21) and V(49) to V(60) for the healthy tissues.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Organs at Risk / radiation effects. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Femur Head / pathology. Femur Head / radiation effects. Humans. Magnetic Resonance Imaging. Male. Organ Size. Prostate / pathology. Prostate / radiation effects. Radiation Injuries / prevention & control. Radiotherapy Dosage. Rectum / pathology. Rectum / radiation effects. Seminal Vesicles / pathology. Seminal Vesicles / radiation effects. Urinary Bladder / pathology. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • HAL archives ouvertes. Full text from .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20570202.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Song YS, Cho KH, Kim KW, Yoon JH, Doo SH, Yang WJ, Cho JY, Lee DW: A Case of Bladder Cancer Found during a Workup for Urge Incontinence. Int Neurourol J; 2010 Aug;14(2):130-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Bladder Cancer Found during a Workup for Urge Incontinence.
  • Irritative urinary symptoms may suggest the possibility of bladder cancer.
  • We report a case of metastatic bladder cancer that was discovered during a workup for urge incontinence in a 65-year-old woman with a history of stomach cancer.
  • She had a medical history of gastrectomy due to stomach cancer 4 years previously.
  • Cystoscopy revealed the presence of suspicious bladder mucosal lesions that were biopsied.
  • The pathology was consistent with metastatic signet-ring cell adenocarcinoma.
  • This case suggests that irritative urinary symptoms can be the first clinical manifestation in patients with bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21120224.001).
  • [ISSN] 2093-6931
  • [Journal-full-title] International neurourology journal
  • [ISO-abbreviation] Int Neurourol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2989472
  • [Keywords] NOTNLM ; Bladder cancer / Stomach cancer / Urge incontinence
  •  go-up   go-down


25. Osunkoya AO, Epstein JI: Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol; 2007 Sep;31(9):1323-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
  • Prostatic urothelial-type adenocarcinoma arises through a process of glandular metaplasia of the prostatic urethral urothelium and subsequent in situ adenocarcinoma sometimes associated with villous adenoma.
  • These prostatic adenocarcinomas are analogous to nonurachal adenocarcinomas arising in the bladder from cystitis glandularis.
  • Only 2 cases of urothelial-type adenocarcinoma from an institution other than our own have been previously described.
  • The distinction between adenocarcinoma from another organ secondarily involving the prostate, usual adenocarcinoma of the prostate, and prostatic urothelial-type adenocarcinoma can present a significant diagnostic challenge and has significant therapeutic implications.
  • Fifteen cases of prostatic urothelial-type adenocarcinoma were retrieved from the consult files of one of the authors.
  • Mean patient age at diagnosis was 72 years (range 58 to 93 y).
  • Bladder primaries were ruled out clinically or pathologically in radical resection specimens.
  • Follow-up was available on all men with a mean of 50.3 months (range 2 to 161 mo).
  • All men presented with urinary obstruction symptoms with 3 (20%) also having mucusuria and 2 (13.3%) also having hematuria.
  • In 8/15 (53%) cases, glandular metaplasia of the prostatic urethra and contiguous transition to adenocarcinoma were identified.
  • Prostatic urothelial-type adenocarcinoma is a rare aggressive cancer arising in the prostate.
  • The differential diagnosis includes conventional prostatic mucinous adenocarcinoma and secondary infiltration from a colonic or bladder adenocarcinoma.
  • Immunohistochemistry for prostate specific antigen, prostate specific acid phosphatase, and high molecular weight cytokeratin along with morphology can help rule out conventional prostate carcinoma. beta-catenin, CDX2, and clinical studies are needed to rule out colonic adenocarcinoma.
  • As prostatic urothelial-type adenocarcinoma is entirely analogous to bladder adenocarcinoma in both, its morphology and immunophenotype, only clinical studies or in some cases pathologic examination of the cystoprostatectomy specimen can exclude infiltration from a primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Mucins / analysis. Prostatic Neoplasms / diagnosis. Urothelium / pathology
  • [MeSH-minor] Acid Phosphatase. Aged. Aged, 80 and over. Cell Differentiation. Diagnosis, Differential. Follow-Up Studies. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Prostate-Specific Antigen / analysis. Protein Tyrosine Phosphatases / analysis. Time Factors. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721186.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Mucins; 0 / beta Catenin; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


26. Barbisan F, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Kirkali Z, Montironi R: Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer? BJU Int; 2009 Apr;103(8):1058-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?
  • OBJECTIVE: To determine the incidence and features of urothelial carcinoma (UC) involving the prostate (UCP) and of prostate adenocarcinoma (PA) in radical cystoprostatectomy (RCP) for bladder cancer.
  • UCP was separately evaluated for UC originating from the urethra and peri-urethral ducts (PUC) and for direct extension of bladder UC.
  • Direct extension of UC from the bladder only was present in 16 (6.5%) patients.
  • Of the 123 patients with incidental prostate cancer, 100 cancers (81.3%) were considered clinically insignificant.
  • Direct extension of UC from the bladder and PA occurred together in the same prostate in 11 (4.4%) patients.
  • UC can arise from extension of trigonal or bladder-neck tumours, proximal prostate ducts/urethra, or from cell implantation from manipulation of vesical neoplasms.
  • The frequent high coincidence of prostate and bladder cancer can be explained by a common pathway of carcinogenesis.
  • [MeSH-major] Cystectomy. Prostatectomy. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology


27. Hongoh S, Nomoto T, Kawakami M, Hanai K, Inatsuchi H, Terachi T: [Complete response to M-FAP chemotherapy for multiple lung metastases after segmental resection of urachal carcinoma : a case report]. Hinyokika Kiyo; 2010 Feb;56(2):107-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystoscopy revealed a papillary tumor at the urinary bladder dome.
  • Abdominal magnetic resonance imaging (MRI) and computed tomography(CT) demonstrated a tumor extending from the umbilicus to the bladder dome.
  • Transurethral resection of bladder tumor (TUR-Bt) was performed and histopathological findings revealed adenocarcinoma.
  • Chest CT and examination of the upper gastrointestinal did not reveal any abnormal findings.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185997.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


28. Goulas V, Exarchou V, Troganis AN, Psomiadou E, Fotsis T, Briasoulis E, Gerothanassis IP: Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells. Mol Nutr Food Res; 2009 May;53(5):600-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells.
  • Olive oil compounds is a dynamic research area because Mediterranean diet has been shown to protect against cardiovascular disease and cancer.
  • In this work, we investigated the antioxidant potency and antiproliferative activity against cancer and endothelial cells of water and methanol olive leaves extracts and analyzed their content in phytochemicals using LC-MS and LC-UV-SPE-NMR hyphenated techniques.
  • Olive-leaf crude extracts were found to inhibit cell proliferation of human breast adenocarcinoma (MCF-7), human urinary bladder carcinoma (T-24) and bovine brain capillary endothelial (BBCE).
  • These phytochemicals demonstrated strong antioxidant potency and inhibited cancer and endothelial cell proliferation at low micromolar concentrations, which is significant considering their high abundance in fruits and vegetables.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194970.001).
  • [ISSN] 1613-4133
  • [Journal-full-title] Molecular nutrition & food research
  • [ISO-abbreviation] Mol Nutr Food Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Plant Extracts
  •  go-up   go-down


29. Allen D, O'Brien T, Pingle P, Chandra A: Endometrioid adenocarcinoma of the bladder. Histopathology; 2005 Feb;46(2):232-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma of the bladder.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693899.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


30. Abe T, Hayashi T, Nakayama J, Kishikawa H, Sekii K, Yoshioka T, Itatani H, Kojima Y, Takahara S: [A case of synchronous double primary cancers of prostate, and bladder in a hemodialysis patient: a case report]. Hinyokika Kiyo; 2005 Oct;51(10):689-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous double primary cancers of prostate, and bladder in a hemodialysis patient: a case report].
  • Cystoscopy revealed papillary tumors on the right lateral bladder wall.
  • Transurethral resection of bladder tumor (TUR-Bt) was performed and histopathological examination showed transitional cell carcinoma, G2, pTa.
  • The histologic diagnosis of the transrectal needle prostate biopsy specimen was moderately differentiated adenocarcinoma.
  • A case of synchronous double primary cancers, comprised of adenocarcinoma of the prostate and transitional cell carcinoma of the urinary blader in a hemodialysis patient has never been previously reported in the Japanese literature.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Transitional Cell / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms / diagnosis. Renal Dialysis. Urinary Bladder Neoplasms / diagnosis


31. Nimmonrat A, Na-ChiangMai W, Muttarak M: Urachal abnormalities: clinical and imaging features. Singapore Med J; 2008 Nov;49(11):930-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT in all cases showed a mass located extraperitoneally in the midline just beneath the rectus abdominis muscle and extending from the umbilicus to the dome of the urinary bladder.
  • Cystography was performed in one patient and it showed indentation to the dome of the urinary bladder with mucosal irregularity.
  • The other five solid masses were found to be adenocarcinoma in three and chronic non-specific inflammation in two cases.
  • CONCLUSION: Preoperative diagnosis of urachal abnormalities may be suggested by clinical presentation and imaging features.
  • [MeSH-major] Adenocarcinoma / diagnosis. Neoplasms / diagnosis. Urachal Cyst / diagnosis. Urachus / abnormalities
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Urologic Diseases / complications. Urologic Diseases / diagnosis. Urologic Diseases / pathology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037562.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


32. Angeletti C, Harvey NR, Khomitch V, Fischer AH, Levenson RM, Rimm DL: Detection of malignancy in cytology specimens using spectral-spatial analysis. Lab Invest; 2005 Dec;85(12):1555-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite low sensitivity (around 60%), cytomorphologic examination of urine specimens represents the standard procedure in the diagnosis and follow-up of bladder cancer.
  • We believe that, in future, this type of methodology could be used as an ancillary test in cytopathology, in a manner analogous to immunostaining, in those situations when a definitive diagnosis cannot be rendered based solely on the morphology.
  • [MeSH-major] Artificial Intelligence. Cytodiagnosis / methods. Urinary Bladder Neoplasms / diagnosis. Urine / cytology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Algorithms. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Humans. Image Processing, Computer-Assisted. Spectrum Analysis. Urinalysis. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200074.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R44 CA88684
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


33. Tong GX, Weeden EM, Hamele-Bena D, Huan Y, Unger P, Memeo L, O'Toole K: Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol; 2008 Sep;32(9):1380-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
  • Recent evidence has showed that nephrogenic adenoma is a true "nephrogenic" lesion derived from the proliferation of exfoliated and implanted renal tubular cells in the urinary tract, a process that closely resembles the formation of endometriosis.
  • We report here that PAX8 was detected in all nephrogenic adenomas (N=35) and clear cell adenocarcinoma of the lower urinary tract (N=7), but not in prostate adenocarcinoma (N=100), adenocarcinoma (N=9), squamous cell carcinoma (N=5), or urothelial carcinoma (N=48) of the urinary bladder and its variants.
  • PAX8 was neither detected in normal urothelium of the urinary bladder nor in prostate glands and stroma.
  • PAX2 was also detected in 2 of the 7 clear cell adenocarcinomas of the lower urinary tract.
  • Expression of PAX8 or PAX2 in both nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract may indicate a possible related tissue origin for these 2 lesions; both may be derived from proliferating renal tubular cells in the urinary tract.
  • In addition, detection of PAX8 or PAX2 in clear cell adenocarcinoma of the lower urinary tract is helpful in differentiating it from urothelial carcinoma and its variants and adenocarcinomas of the urinary bladder or of the prostate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenoma / metabolism. Biomarkers, Tumor / analysis. Paired Box Transcription Factors / biosynthesis. Urologic Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670350.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


34. Subramanya D, Grivas PD, Styler M: Appendiceal carcinoma: a diagnostic and therapeutic challenge. Postgrad Med; 2008 Nov;120(4):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initially, the diagnostic investigation in our patient was focused on urinary tract disorders, but ultimately resulted in finding a mucinous appendiceal carcinoma.
  • The carcinoma had invaded the urinary bladder and was disseminated in the peritoneal cavity.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020371.001).
  • [ISSN] 1941-9260
  • [Journal-full-title] Postgraduate medicine
  • [ISO-abbreviation] Postgrad Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Yamashita R, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K: Urothelial carcinoma (clear cell variant) diagnosed with useful immunohistochemistry stain. Int J Urol; 2006 Nov;13(11):1448-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On evaluation, a papillary pedunculated tumor was detected in the left wall of the urinary bladder.
  • A transurethral resection of the bladder tumor (TUR-Bt) was performed in July 2005.
  • The pathological diagnosis was difficult due to diffuse clear cell appearance.
  • Immunohistochemistry stain showed urothelial carcinoma, not metastasis of the renal cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Immunohistochemistry / methods. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Keratin-7 / analysis. Male. Reproducibility of Results. Sensitivity and Specificity. Urothelium / chemistry. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083402.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Keratin-7
  •  go-up   go-down


36. Novak TE, Lakshmanan Y, Frimberger D, Epstein JI, Gearhart JP: Polyps in the exstrophic bladder. A cause for concern? J Urol; 2005 Oct;174(4 Pt 2):1522-6; discussion 1526
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyps in the exstrophic bladder. A cause for concern?
  • Malignancy in exstrophic bladders has been reported most frequently in untreated adults and those undergoing surgical treatments which involve the mixing of fecal and urinary streams.
  • The question of whether the closed exstrophic bladder has a similar potential for malignancy has not been resolved.
  • The polypoid appearance of the exstrophic bladder template raises the concern of premalignant lesions.
  • MATERIALS AND METHODS: Under institutional board review, the slides of 38 patients with classic bladder exstrophy who had polyps excised at the time of closure were reviewed by a single genitourinary pathologist (JIE).
  • CONCLUSIONS: Although no dysplasia was noted, cystitis glandularis is associated with the development of adenocarcinoma of the bladder.
  • [MeSH-major] Bladder Exstrophy / complications. Bladder Exstrophy / surgery. Polyps / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148644.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Hungerhuber E, Bach E, Hartmann A, Frimberger D, Stief C, Zaak D: Adenocarcinoma of the bladder following nephrogenic adenoma: a case report. J Med Case Rep; 2008;2:164
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the bladder following nephrogenic adenoma: a case report.
  • We report a case of post-traumatic nephrogenic adenoma in a young patient without immunosuppression, which transformed into an adenocarcinoma of the bladder.
  • CASE PRESENTATION: A 25-year-old man had a traumatic bladder perforation caused by a car accident.
  • After physical recovery from the accident, he developed a neurogenic bladder and recurrent urinary tract infections.
  • He presented with nephrogenic adenoma of the bladder 18 months after the accident.
  • The initial pathologic findings were benign, however, the last resection revealed that the former benign adenoma had transformed into a moderately differentiated adenocarcinoma of the bladder (tumor present but no invasion, multifocal, no lymph nodes involved, no metastasis, grade 2).
  • However, patients with nephrogenic adenoma under immunosuppression and patients with neurogenic bladder dysfunction appear to be at a higher risk of developing bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1988 Jan;139(1):130-1 [3121867.001]
  • [Cites] Histopathology. 1990 Jun;16(6):601-4 [2376401.001]
  • [Cites] Urology. 1987 Mar;29(3):237-41 [3548004.001]
  • [Cites] Am J Surg Pathol. 1986 Apr;10(4):268-75 [3706613.001]
  • [Cites] J Urol. 1968 Oct;100(4):466-9 [5677385.001]
  • [Cites] J Urol. 1984 Aug;132(2):263-5 [6737573.001]
  • [Cites] J Urol. 1981 Dec;126(6):824-6 [6798226.001]
  • [Cites] J Urol. 1996 Jul;156(1):41-4 [8648834.001]
  • [Cites] Urology. 1997 Nov;50(5):690-6 [9372876.001]
  • [Cites] Urology. 1999 Feb;53(2):292-7 [9933042.001]
  • [Cites] Cancer. 2002 Apr 25;96(2):117-22 [11954029.001]
  • [Cites] N Engl J Med. 2002 Aug 29;347(9):653-9 [12200552.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2381-2 [14634422.001]
  • [Cites] J Urol. 1950 Nov;64(5):657-70 [14785074.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):117-20 [16360424.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1231-7 [17667548.001]
  • [Cites] Northwest Med. 1949 Mar;48(3):182-5 [18114097.001]
  • [Cites] J Urol. 1988 Jan;139(1):45-7 [3275801.001]
  • (PMID = 18485239.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2396656
  •  go-up   go-down


38. Pekáriková A, Sánchez D, Palová-Jelínková L, Simsová M, Benes Z, Hoffmanová I, Drastich P, Janatková I, Mothes T, Tlaskalová-Hogenová H, Tucková L: Calreticulin is a B cell molecular target in some gastrointestinal malignancies. Clin Exp Immunol; 2010 May;160(2):215-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using enzyme-linked immunosorbent assay (ELISA), we found immunoglobulin (Ig)A and/or IgG anti-calreticulin antibodies in sera of approximately 63% of patients with hepatocellular carcinoma (HCC), 57% of patients with colorectal adenocarcinoma (CRA) and 47% of patients with pancreatic adenocarcinoma (PACA), while healthy controls, patients with viral hepatitis C and with chronic pancreatitis reached only 2%, 20% and 31% seropositivity, respectively.
  • Significantly elevated mean levels of IgG anti-calreticulin antibodies (P < 0.001) were detected in patients with HCC (121.9 +/- 94.2 AU), gall bladder adenocarcinoma (118.4 +/- 80.0 AU) and PACA (88.7 +/- 55.6 AU) when compared to healthy controls (56.7 +/- 22.9 AU).
  • [MeSH-major] Adenocarcinoma / immunology. Antibodies, Neoplasm / immunology. Autoantibodies / immunology. Autoantigens / immunology. B-Lymphocytes / immunology. Calreticulin / immunology. Carcinoma, Hepatocellular / immunology. Colorectal Neoplasms / immunology. Liver Neoplasms / immunology. Neoplasm Proteins / immunology. Pancreatic Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2009 Mar;15(1):89-90 [18925427.001]
  • [Cites] Biochem J. 2009 Feb 1;417(3):651-66 [19133842.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1117-20 [10706133.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):1056-61 [10763959.001]
  • [Cites] J Autoimmun. 2000 Dec;15(4):441-9 [11090243.001]
  • [Cites] J Clin Invest. 2001 Nov;108(10):1411-5 [11714730.001]
  • [Cites] Mol Cell Proteomics. 2002 Mar;1(3):197-203 [12096119.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43 [12582023.001]
  • [Cites] Clin Chem. 2003 Jul;49(7):1206-8 [12816927.001]
  • [Cites] Clin Exp Immunol. 2003 Oct;134(1):143-50 [12974767.001]
  • [Cites] J Autoimmun. 2003 Dec;21(4):383-92 [14624761.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5504-10 [15289361.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):1149-55 [15375567.001]
  • [Cites] J Mol Biol. 1973 Nov 15;80(4):575-99 [4204102.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):942-3 [9797714.001]
  • [Cites] Hybridoma. 1998 Oct;17(5):431-5 [9873988.001]
  • [Cites] J Exp Med. 1999 Mar 1;189(5):797-802 [10049943.001]
  • [Cites] Scand J Immunol. 1999 May;49(5):466-73 [10320638.001]
  • [Cites] Hum Immunol. 1999 Jun;60(6):510-5 [10408800.001]
  • [Cites] Cancer Detect Prev. 2005;29(3):241-8 [15896923.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):187-98 [16297705.001]
  • [Cites] Nat Med. 2007 Jan;13(1):54-61 [17187072.001]
  • [Cites] Nat Biotechnol. 2007 Feb;25(2):192-3 [17287754.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):209-16 [17276050.001]
  • [Cites] Expert Opin Biol Ther. 2007 Apr;7(4):493-507 [17373901.001]
  • [Cites] Tissue Antigens. 2007 Jul;70(1):1-11 [17559575.001]
  • [Cites] Immunol Rev. 2007 Dec;220:22-34 [17979837.001]
  • [Cites] J BUON. 2008 Jan-Mar;13(1):101-7 [18404795.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2476-83 [18413840.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3830-7 [18683965.001]
  • [Cites] Clin Exp Immunol. 2008 Sep;153(3):351-9 [18637103.001]
  • [Cites] Cancer Lett. 2009 Aug 18;281(1):8-23 [19091462.001]
  • (PMID = 20030668.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Autoantibodies; 0 / Autoantigens; 0 / Calreticulin; 0 / Epitopes; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2857944
  •  go-up   go-down


39. Singh I, Hudson JE, Hemal AK: Robot-assisted laparoscopic prostatectomy for a giant prostate with retrieval of vesical stones. Int Urol Nephrol; 2010 Sep;42(3):615-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: An elderly, male with a BMI of 32.49, clinically diagnosed as a case of giant BPH (prior negative prostate biopsy) with vesical stones and severe LUTS, was successfully managed by modified robot assisted laparoscopic technique of prostatectomy with removal of bladder stones.
  • The final histology was predominant BPH with an incidental focal adenocarcinoma within the distal left prostate.
  • Minimally invasive management of massively enlarged prostate with associated bladder stones is a challenging task.
  • The present case of giant prostate enlargement (incidental localized prostate cancer) with vesical stones was successfully managed by a combination of robotic prostatectomy and removal of bladder stones under flexible endoscopic guidance.
  • To the best of our knowledge the present case is the largest (384 g) reported case of cancer prostate (concomitant vesical stone), to be removed by minimally invasive robot assisted laparoscopic technique in the English literature (PubMed™).
  • [MeSH-major] Laparoscopy. Prostatectomy. Prostatic Hyperplasia / surgery. Robotics. Urinary Bladder Calculi / surgery
  • [MeSH-minor] Aged. Cystoscopy. Humans. Incidental Findings. Male. Prostate / pathology. Prostatic Neoplasms / diagnosis


40. Chung SD, Yu HJ, Lin WC, Huang KH: Metastatic prostatic adenocarcinoma in an inguinal hernia sac in a patient with undetectable serum prostate specific antigen level. J Formos Med Assoc; 2007 May;106(5):397-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostatic adenocarcinoma in an inguinal hernia sac in a patient with undetectable serum prostate specific antigen level.
  • Metastatic prostate cancer found within the hernia sac contents is a rare clinical manifestation.
  • We report a 64-year-old male patient who presented with rare clinical features of prostate cancer.
  • A focal metastasis of prostate cancer was incidentally found in an incised inguinal hernia sac 5 years after radical prostatectomy.
  • However, his serum PSA level started rising 12 months later and bladder invasion as well as a mass in the cul-de-sac was identified subsequently.


41. Wolk M, Martin JE, Reinus C: Development of fetal haemoglobin-blood cells (F cells) within colorectal tumour tissues. J Clin Pathol; 2006 Jun;59(6):598-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To evaluate the sources of fetal haemoglobin (HbF) as an indicator in cancer.
  • An immunohistochemical study was carried out on some of the most common kinds of cancer.
  • METHODS: Immunoaffinity-purified anti-HbF was immunohistochemically used to study F cell distribution in the following cancers: colorectal adenocarcinoma, urinary bladder transitional cell carcinoma, brain tumours, lung carcinoma, breast adenocarcinoma, leukaemia, Burkitt's lymphoma and endometrial carcinoma.
  • RESULTS: In colorectal adenocarcinoma, HbF-containing red blood cells (FRBC) were present within thin-walled vessels or were disposed in dense clusters within the tumour.
  • In half of the cases with transitional cell carcinoma of the urinary bladder, regional intratumoral blood vessels were found to contain 5-50% FRBC.
  • In the other tumours examined, F cells were not observed.
  • [MeSH-major] Adenocarcinoma / blood supply. Colorectal Neoplasms / blood supply. Fetal Hemoglobin / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Brain Neoplasms / blood supply. Breast Neoplasms / blood supply. Erythroblasts / metabolism. Female. Humans. Leukemia / blood. Lung Neoplasms / blood supply. Male. Middle Aged. Urinary Bladder Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blut. 1990 Jul;61(1):17-20 [1696840.001]
  • [Cites] Tumour Biol. 1991;12(1):45-51 [1705048.001]
  • [Cites] Blood. 1995 Jul 1;86(1):323-8 [7795240.001]
  • [Cites] Pediatr Res. 1995 Oct;38(4):555-63 [8559609.001]
  • [Cites] Blood. 1996 Jan 15;87(2):557-66 [8555477.001]
  • [Cites] Immunol Today. 1998 May;19(5):228-36 [9613041.001]
  • [Cites] Semin Hematol. 2004 Oct;41(4 Suppl 6):3-10 [15534851.001]
  • [Cites] Development. 1999 Nov;126(22):5073-84 [10529424.001]
  • [Cites] Blood. 2000 May 1;95(9):2967-74 [10779447.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1847-52 [11172039.001]
  • [Cites] Haematologica. 2002 Mar;87(3):323-5 [11869947.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1478-83 [12145688.001]
  • [Cites] Ann Hematol. 2002 Sep;81(9):548-50 [12373361.001]
  • [Cites] Blood. 2003 Jan 15;101(2):492-7 [12393703.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1669-76 [12406884.001]
  • [Cites] Clin Chem Lab Med. 2003 May;41(5):646-51 [12812262.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1929-33 [14592835.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):740-5 [15220368.001]
  • [Cites] Ann N Y Acad Sci. 1974 Nov 29;241(0):638-52 [4611309.001]
  • [Cites] Acta Haematol. 1977;58(5):288-93 [74180.001]
  • [Cites] J Pathol. 1981 May;134(1):71-80 [6169819.001]
  • (PMID = 16469830.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9034-63-3 / Fetal Hemoglobin
  • [Other-IDs] NLM/ PMC1860403
  •  go-up   go-down


42. Tavora F, Epstein JI: Bladder cancer, pathological classification and staging. BJU Int; 2008 Nov;102(9 Pt B):1216-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer, pathological classification and staging.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035884.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Taverna G, Corinti M, Colombo P, Grizzi F, Severo M, Piccinelli A, Giusti G, Benetti A, Zucali PA, Graziotti P: Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation. BMC Cancer; 2010;10:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation.
  • BACKGROUND: Appendiceal adenocarcinoma is rare with a frequency of 0.08% of all surgically removed appendices.
  • Few cases of appendiceal carcinoma infiltrating the bladder wall for spatial contiguity have been documented.
  • CASE PRESENTATION: A case is reported of a 45-years old woman with mucinous cystadenocarcinoma of the appendix with bladder metastasis.
  • Although ultrasonography and voided urinary cytology were negative, abdomen computed tomography (CT) scan and cystoscopy and subsequent pathological examination revealed a mass exclusively located in the anterior wall of the bladder.
  • Histopathology of the transurethral bladder resection revealed a bladder adenocarcinoma [6 cm (at the maximum diameter) x 2,5 cm; approximate weight: 10 gr] with focal mucinous aspects penetrating the muscle and perivisceral fat.
  • The subsequent pathological examination revealed a mucinous cystadenocarcinoma of the appendix with metastatic cells colonising the anterior bladder wall and several colic lymph nodes.
  • CONCLUSIONS: The rarity of the appendiceal carcinoma invading the urinary bladder and its usual involvement of nearest organs and the posterior bladder wall, led us to describe this case which demonstrates the ability of the appendiceal cancer to metastasize different regions of urinary bladder.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Cystadenocarcinoma, Mucinous / secondary. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2001 Apr;8(4):196-8 [11260355.001]
  • [Cites] Hinyokika Kiyo. 2002 Jun;48(6):351-4 [12166235.001]
  • [Cites] J Urol. 1980 Apr;123(4):590-1 [6245280.001]
  • [Cites] Can J Surg. 1982 Sep;25(5):553-5 [7116255.001]
  • [Cites] J Urol. 1987 Sep;138(3):617-8 [3041057.001]
  • [Cites] J Dig Dis. 2008 Aug;9(3):175-7 [18956597.001]
  • [Cites] Br J Urol. 1996 Aug;78(2):305-6 [8813936.001]
  • [Cites] Urol Int. 1997;58(2):124-7 [9096277.001]
  • [Cites] World J Gastroenterol. 2005 Aug 14;11(30):4761-3 [16094726.001]
  • [Cites] Int Urol Nephrol. 2006;38(3-4):481-2 [17160444.001]
  • [Cites] J Urol. 1995 Apr;153(4):1220-1 [7869505.001]
  • (PMID = 20178637.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2836301
  •  go-up   go-down


44. Hasegawa Y, Kato Y, Wakita T, Hayashi N, Tsukamoto K: [Carcinoma of the urachus: a case report]. Hinyokika Kiyo; 2005 Mar;51(3):191-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystoscopy revealed a broad-stalk, nonpapillary tumor at the urinary bladder dome, and cold-punch biopsy proved it to be a mucus-producing adenocarcinoma.
  • Abdominal managnetic resonance imaging demonstrated a tumor extending from the umbilicus to the bladder dome, and chest computed tomography (CT) demonstrated a small lung tumor with calcification.
  • Examination of the upper gostroinstestinal tract, barium enema, and colon fiberscopy did not reveal abnormalities.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urachus

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852675.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


45. Suzuki T, Togo Y, Yasuda K, Yamamoto H, Kokura K, Nagareda T: [Prostatic duct adenocarcinoma with pagetoid spread on the glans penis: a case report]. Hinyokika Kiyo; 2006 Nov;52(11):887-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatic duct adenocarcinoma with pagetoid spread on the glans penis: a case report].
  • The patient underwent total cystoprostatectomy under the diagnosis of urothelial carcinoma of the urinary bladder four years earlier.
  • At the time, the prostatectomy specimen incidentally revealed a prostatic acinar adenocarcinoma at the bilateral peripheral zone.
  • A skin biopsy of the erythema revealed intraepithelial Paget's cells, and the patient underwent total penectomy under the diagnosis of extramammary Paget's disease.
  • Re-examination of the previous prostatectomy specimen revealed prostatic duct adenocarcinoma with prostatic acinar adenocarcinoma.
  • Therefore, the final diagnosis was prostatic duct adenocarcinoma with Pagetoid spread to the glans penis.
  • [MeSH-major] Adenocarcinoma / pathology. Paget Disease, Extramammary / pathology. Penile Neoplasms / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma / pathology. Humans. Male. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17176876.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Torres Gómez FJ, Torres Olivera FJ, Torres Gómez A: [Polypoid cystitis associated with glandular cystic cystitis]. Arch Esp Urol; 2007 Jul-Aug;60(6):692-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Polypoid cystitis and intestinal metaplasia are well-known lesions of the bladder.
  • METHODS: We report the case of one patient with both lesions identified synchronically in the bladder.
  • RESULTS: Although these lesions are not neoplastic, there are evidences supporting a possible degeneration of the metaplastic epithelium to adenocarcinoma.
  • CONCLUSIONS: The diagnosis of both lesions is histological and there are not clinical tests or image studies that could enable identification of the real nature of these lesions.
  • [MeSH-minor] Aged. Cysts / pathology. Humans. Intestines / pathology. Male. Metaplasia / pathology. Polyps / pathology. Urinary Bladder / pathology. Urinary Bladder Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17847746.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


47. Hamano A, Udagawa K, Nomura S, Ishida T: Inguinal metastasis of a bladder mixed carcinoma with predominant adenocarcinoma component. Scand J Urol Nephrol; 2006;40(1):75-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inguinal metastasis of a bladder mixed carcinoma with predominant adenocarcinoma component.
  • We report a case of urinary bladder mixed carcinoma with inguinal metastasis.
  • Histological examination of the transurethral resection specimens revealed adenocarcinoma with small foci of squamous and transitional cell carcinomas.
  • [MeSH-major] Adenocarcinoma / secondary. Lymph Nodes / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452061.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


48. Gatto A, Falvo L, Sebastiani S, Roncolini G, Pinna G: Triple synchronous tumours of the urinary system with different histologies: a case report. Chir Ital; 2009 May-Jun;61(3):381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple synchronous tumours of the urinary system with different histologies: a case report.
  • We present the case report of a male patient with a diagnosis of synchronous kidney, bladder and prostate tumours with different histologies: renal oncocytoma, urothelial carcinoma of the bladder, and adenocarcinoma of the prostate.
  • [MeSH-major] Cystectomy. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Nephrectomy. Prostatectomy. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenoma, Oxyphilic / pathology. Aged. Carcinoma / pathology. Humans. Male. Risk Factors. Smoking / adverse effects. Treatment Outcome


49. Yan X, Li G, Shang H, Wang G, Chen L, Han Y: Complications of laparoscopic radical hysterectomy and pelvic lymphadenectomy--experience of 117 patients. Int J Gynecol Cancer; 2009 Jul;19(5):963-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective study was conducted on LRH + LPL in 117 cases of cervical cancer with International Federation of Gynecology and Obstetrics stages Ib (n = 96) and II a (n = 21) from August 1998 to December 2006.
  • One patient had a common iliac vein laceration that could not be controlled laparoscopically after failing to deal with the injured branch of common iliac vein.
  • One case of stage IIa with a bladder laceration longer than 3 cm was converted to laparotomy during the early stages of the learning curve.
  • Postoperative complications occurred in 38.5% (n = 45) of the patients, including 38 patients with urinary retention who exhibited complete resolution within 6 months by intermittent training and catheterization, 4 with lymphocyst who underwent conservation treatment, 1 with ureteral fistula that was treated by cystoscopic placement of double-J ureteral stents, 1 with mild adynamic bowel obstruction who received conservative management, and 1 with vesicovaginal fistula that was closed by conservative treatment.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Carcinoma, Adenosquamous / complications. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult


50. Quek ML, Barry P, Stein JP, Lieskovsky G, Ginsberg DA: Combined radical prostatectomy and bladder augmentation for concomitant prostate cancer and detrusor instability. Urology; 2005 May;65(5):964-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined radical prostatectomy and bladder augmentation for concomitant prostate cancer and detrusor instability.
  • OBJECTIVES: To determine the outcomes of a select cohort of patients with severe voiding dysfunction, refractory to medical management, and a concomitant diagnosis of prostate cancer, who were treated with radical prostatectomy and augmentation enterocystoplasty.
  • METHODS: Four men with biopsy-proven prostatic adenocarcinoma, as well as a diagnosis of severe overactive bladder, underwent combined radical retropubic prostatectomy and augmentation enterocystoplasty.
  • CONCLUSIONS: The concomitant diagnosis of prostate cancer and severe detrusor instability may be difficult to treat.
  • The results of our study have shown that for those desiring surgical management for their prostate cancer, a combined bladder augmentation and radical prostatectomy may be performed with minimal added morbidity and significantly improved voiding function in the properly selected individual.
  • [MeSH-major] Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / surgery. Urinary Bladder / surgery. Urinary Bladder Diseases / surgery


51. Waalkes MP, Liu J, Ward JM, Diwan BA: Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen. Toxicol Appl Pharmacol; 2006 Sep 15;215(3):295-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen.
  • Arsenic alone also increased lung adenocarcinoma, adrenal cortical adenoma and renal cystic tubular hyperplasia compared to control.
  • The treatments alone did not impact urinary bladder carcinogenesis, but arsenic plus TAM significantly increased formation of urinary bladder transitional cell tumors (papilloma and carcinoma; 13%) compared to control (0%).
  • Urinary bladder proliferative lesions (combined tumors and hyperplasia) were also increased by arsenic plus TAM (40%) or arsenic plus DES (43%) compared to control (0%) or the treatments alone.
  • Urinary bladder proliferative lesions occurred in the absence of any evidence of uroepithelial cytotoxic lesions.
  • Urinary bladder lesions and hepatocellular carcinoma induced by arsenic plus TAM and/or DES overexpressed estrogen receptor-alpha, indicating that aberrant estrogen signaling may have been a factor in the enhanced carcinogenic response.
  • Thus, in male CD1 mice, gestational arsenic exposure alone induced liver adenoma and carcinoma, lung adenocarcinoma, adrenal adenoma and renal cystic hyperplasia.
  • In utero arsenic also initiated urinary bladder tumor formation when followed by postnatal TAM and uroepithelial proliferative lesions when followed by TAM or DES.
  • [MeSH-major] Arsenic / toxicity. Diethylstilbestrol / toxicity. Liver Neoplasms / etiology. Tamoxifen / toxicity. Urinary Bladder Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712894.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogens, Non-Steroidal; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic
  •  go-up   go-down


52. Brock M, Martin W, Sommerer F, Noldus J: [Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?]. Urologe A; 2009 Jul;48(7):770-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?].
  • Ductal adenocarcinoma of the prostate is a rare entity.
  • The lack of correlation between the prostate-specific antigen value and the tumor stage, as well as early dissemination, are major differences from acinar cancer.
  • Urinary obstruction and hematuria lead to clinical assessment.
  • We report the case of a 64-year-old man with ductal prostate cancer who underwent radical cystectomy followed by androgen deprivation therapy.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Carcinoma, Ductal / secondary. Carcinoma, Ductal / therapy. Cystectomy / methods. Prostatic Neoplasms / therapy. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Urol. 2008 Jan;5(1):55-8 [18185514.001]
  • [Cites] Cancer. 1967 Oct;20(10):1715-22 [4168340.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Am J Clin Pathol. 2006 Aug;126(2):302-9 [16891207.001]
  • [Cites] Cancer. 2007 May 15;109(10):2011-5 [17420979.001]
  • [Cites] J Urol. 2005 Dec;174(6):2186-90 [16280761.001]
  • [Cites] Cancer. 1976 May;37(5):2255-62 [130969.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1471-9 [10584700.001]
  • [Cites] Urol Oncol. 2007 Jan-Feb;25(1):53-5 [17208139.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):57-9 [16462155.001]
  • [Cites] BJU Int. 2008 Nov;102(10):1369-74 [18793296.001]
  • [Cites] Semin Diagn Pathol. 1988 Aug;5(3):301-11 [2845546.001]
  • (PMID = 19352617.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


53. Coote JH, Wylie JP, Cowan RA, Logue JP, Swindell R, Livsey JE: Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Dose escalation for prostate cancer improves biological control but with a significant increase in late toxicity.
  • Recent estimates of low alpha/beta ratio for prostate cancer suggest that hypofractionation may result in biological advantage.
  • METHODS AND MATERIALS: Eligible men had T2-3N0M0 adenocarcinoma prostate, and either Gleason score >or= 7 or prostate-specific antigen 20-50 ng/L.
  • At 2 years, there was 4% Grade 2 bowel and 4.25% Grade 2 bladder toxicity.
  • There was no Grade 3 or 4 bowel toxicity; one patient developed Grade 3 bladder toxicity.
  • UCLA data showed a slight improvement in urinary function at 2 years compared with pretreatment.
  • CONCLUSIONS: These data demonstrate that hypofractionated radiotherapy using IMRT for prostate cancer is well tolerated with minimal late toxicity at 2 years posttreatment.
  • [MeSH-minor] Adenocarcinoma. Aged. Aged, 80 and over. Dose Fractionation. Humans. Intestines / radiation effects. Male. Middle Aged. Prostate-Specific Antigen / blood. Radiation Injuries / complications. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131179.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


54. Sachedina N, De Los Santos R, Manoharan M, Soloway MS: Total prostatectomy and lymph node dissection may be done safely without pelvic drainage: an extended experience of over 600 cases. Can J Urol; 2009 Aug;16(4):4721-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From our experience with 846 patients, we contend that patient safety and efficacy is not compromised by selectively omitting a pelvic drain.
  • MATERIALS AND METHODS: TP/LND was performed in 846 patients with clinically localized prostate adenocarcinoma.
  • After the prostate was removed and the anastomotic sutures tied, saline was instilled into the bladder through the urethral catheter.
  • When comparing the incidence of urinary retention, hematuria, anastomotic stricture, pelvic fluid collections, hematuria, and thrombolic events, there was no significant difference between patients with and without a drain.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision / methods. Prostatectomy / methods. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671222.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


55. Nese N, Kesici G, Lekili M, Isisag A: Urachal urothelial carcinoma diagnosed at a radical prostatectomy operation: a case report. Anal Quant Cytol Histol; 2010 Jun;32(3):174-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostatic adenocarcinoma (PCa) (Gleason score 6) was diagnosed by needle biopsies.
  • After the diagnosis of high grade, muscle invasive UCa with intact mucosa on frozen examination of the dome of bladder wall during the radical prostatectomy operation (RPO), partial cystectomy was performed.
  • Six months after the diagnosis, an undifferentiated tumor was detected in a bladder transurethral resection specimen; thus, chemotherapy was given.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701072.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA, Watson DK: Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol; 2006 Jun;175(6):2312-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.
  • We investigated the expression pattern of survivin in the tumors of patients with bladder cancer and assessed the diagnostic potential of RT-PCR detection of survivin mRNA in urine.
  • MATERIALS AND METHODS: RT-PCR was used to analyze mRNA expression of survivin in 161 cases of bladder cancer, including TCC in 97, SCC in 53 and adenocarcinoma in 11, and their matched nontumor tissues.
  • Urine specimens (50 ml) were collected from 84 patients in whom bladder cancer was documented by transurethral resection or biopsy, 41 with nonbladder cancer urological diseases and 42 healthy volunteers.
  • RESULTS: Survivin expression was detected in all bladder cancer tissues.
  • In contrast, survivin was not detectable in normal urothelium specimens.
  • Urinary survivin was detected in urine samples from 51 of 53 patients with TCC, 22 of 25 with SCC and 6 of 6 with adenocarcinoma.
  • Survivin mRNA was not detected in any healthy volunteers.
  • Positive results were obtained in 2 patients with renal cell carcinoma, 1 with hematuria and 1 with a contracted bladder but in none with other urological diseases.
  • CONCLUSIONS: Survivin mRNA detection in urine sediment using RT-PCR shows high sensitivity and specificity for bladder cancer.
  • [MeSH-major] Microtubule-Associated Proteins / genetics. Neoplasm Proteins / genetics. RNA, Messenger / urine. Reverse Transcriptase Polymerase Chain Reaction. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697865.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


57. Abdel Wahab AH, Abo-Zeid HI, El-Husseini MI, Ismail M, El-Khor AM: Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder. J Egypt Natl Canc Inst; 2005 Dec;17(4):260-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder.
  • Non-random chromosome deletion and LOH at specific chromosomal regions are identified in a number of common human cancers including carcinoma of the bladder, which is considered the most predominant cancer in Egypt due to the prevalence of schistosomiasis.
  • PURPOSE: The main objective of the present study is to clarify the role of chromosomes 8 and 9 in the establishment and/or progression of schistosomiasis-related bladder cancer through detection of LOH of 8 microsatellite markers on both chromosomes.
  • It also aims to compare the LOH pattern of the tested markers between schistosomiasis- associated and non schistosomiasis-associated bladder cancer.
  • MATERIAL AND METHODS: To achieve this purpose, DNA was extracted from the tumor specimens and the corresponding peripheral blood samples of 42 primary bladder cancer patients (schistosomal and non schistosomal).
  • Twenty nine of these were diagnosed as squamous cell type (SCC), 11 were transitional (TCC), and 2 were adenocarcinoma (with different stages and grades).
  • CONCLUSION: Our data indicate that more than one tumor suppressor gene on chromosomes 8 and 9 are involved in high grades of bladder carcinogenesis, one at 8p12 and another at 8q21.1 regions.
  • Also, a region at 8q23-quarter may harbor tumor suppressor gene that involved in metastasis of bladder cancer.
  • Finally, the present study shows no line of demarcation between schistosomiasis-associate and non schistosomiasis-associated bladder cancer in terms of LOH of the tested microsatellite markers on chromosome 8 and 9.
  • This suggests that data obtained from schistosoma-associated bladder cancer can be extrapolated to bladder cancer induced by a schistosomiasis independent mechanism.
  • [MeSH-major] Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Loss of Heterozygosity. Schistosomiasis haematobia / complications. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102820.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


58. Meng Z, Tan J, Dong F, Jia Q, Zhang F: Demonstration of a congenital urine bladder diverticulum by 99mTc-MDP SPET/CT scan in a female with bone metastases. Hell J Nucl Med; 2009 Sep-Dec;12(3):276-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demonstration of a congenital urine bladder diverticulum by 99mTc-MDP SPET/CT scan in a female with bone metastases.
  • Urine bladder diverticula are usually asymptomatic, therefore they are incidentally diagnosed during examinations for other purposes.
  • A Chinese patient, with a history of pulmonary adenocarcinoma first underwent a technetium-99m methylene diphosphonate whole-body bone scan.
  • In addition to multiple skeletal metastases, abnormal shape of the urine bladder was also noted, which overlapped the superior ramus of the right pubic bone.
  • In order to: a) better delineate the shape and structure of the urine bladder;.
  • b) visualize the pubic bone and c) detect the exact location and structural changes of skeletal lesions in the lumbosacral region, single photon emission tomography/computerized tomography (SPET/CT) scan of this region was performed immediately, and demonstrated: a) a big urine bladder diverticulum in the right hemipelvis;.
  • An overview of the etiology, histopathology, complications, management and imaging of urine bladder diverticulum is also presented.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Diverticulum / diagnosis. Lung Neoplasms / diagnosis. Urinary Bladder Diseases / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Incidental Findings. Radiopharmaceuticals. Subtraction Technique. Technetium Tc 99m Medronate. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936344.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


59. Santanam L, He T, Yudelev M, Forman JD, Orton CG, Heuvel FV, Maughan RL, Burmeister J: Intensity modulated neutron radiotherapy for the treatment of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys; 2007 Aug 1;68(5):1546-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity modulated neutron radiotherapy for the treatment of adenocarcinoma of the prostate.
  • PURPOSE: This study investigates the enhanced conformality of neutron dose distributions obtainable through the application of intensity modulated neutron radiotherapy (IMNRT) to the treatment of prostate adenocarcinoma.
  • The IMNRT plans were created retrospectively for 5 patients previously treated for prostate adenocarcinoma using fast neutron therapy (FNT), and a comparison of these plans is presented.
  • Dose distributions and dose-volume histograms (DVHs) were analyzed and plans were evaluated based on percentage volumes of rectum and bladder receiving 95%, 80%, and 50% (V(95), V(80), V(50)) of the prescription dose, and on V(60) for both the femoral heads and GM(muscle) group.
  • Use of IMNRT provided reductions in rectum V(95) and V(80) of 10% (2-27%) and 13% (5-28%), respectively, and reductions in bladder V(95) and V(80) of 12% (3-26%) and 4% (7-10%), respectively.
  • The IMNRT technique provides a substantial reduction in normal tissue dose in the treatment of prostate cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Algorithms. Neutrons / therapeutic use. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Femur Head / radiation effects. Humans. Male. Muscle, Skeletal / radiation effects. Radiation Injuries / prevention & control. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted / methods. Rectum / radiation effects. Seminal Vesicles / radiation effects. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674984.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Lim M, Adsay NV, Grignon D, Osunkoya AO: Urothelial carcinoma with villoglandular differentiation: a study of 14 cases. Mod Pathol; 2009 Oct;22(10):1280-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the urinary bladder may have a variety of histological patterns.
  • However, urothelial carcinomas with both villous and glandular features have not been well characterized.
  • A concurrent high-grade papillary urothelial carcinoma component was identified in 11 cases (79%), micropapillary component in 5 (36%) cases, in-situ urothelial carcinoma component in 3 cases (21%), plasmacytoid component in 3 cases (21%), invasive adenocarcinoma in 2 cases, sarcomatoid carcinoma component in one case (14%), and small-cell carcinoma component in 1 case (7%).
  • [MeSH-major] Carcinoma / pathology. Cell Differentiation. Neoplasms, Glandular and Epithelial / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Aged, 80 and over. Biopsy. Carcinoma in Situ / pathology. Carcinoma, Small Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593329.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Sharma DN, Thulkar S, Goyal S, Shukla NK, Kumar S, Rath GK, Julka PK, Saini G, Bahl A: Revisiting the role of computerized tomographic scan and cystoscopy for detecting bladder invasion in the revised FIGO staging system for carcinoma of the uterine cervix. Int J Gynecol Cancer; 2010 Apr;20(3):368-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting the role of computerized tomographic scan and cystoscopy for detecting bladder invasion in the revised FIGO staging system for carcinoma of the uterine cervix.
  • INTRODUCTION: Recent revision of the International Federation of Gynecology and Obstetrics (FIGO) staging system for the cervix encourages use of computerized tomography (CT) and magnetic resonance imaging and does not recommend cystoscopy as a mandatory investigation.
  • But the revision has not defined which patients should undergo cystoscopy.
  • Our study aims to revisit the role of CT scan and cystoscopy for detecting bladder invasion so that we can select patients for cystoscopy.
  • METHODS: We reviewed case records of all cervical cancer patients who underwent abdominopelvic CT scan besides standard FIGO staging workup (including cystoscopy) and treatment with radiotherapy or concurrent chemoradiotherapy between years 2003 and 2005.
  • Patients showing bladder invasion on CT scan or cystoscopy were identified and separately analyzed.
  • Considering cystoscopy as the standard reference investigation, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the CT scan for bladder invasion were calculated.
  • Forty-three (14%) patients had bladder invasion on CT scan, and 17 (5.5%) had cystoscopy-confirmed invasion.
  • No patient showing absence of bladder invasion on CT scan showed cystoscopy-confirmed invasion.
  • The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the CT scan for bladder invasion were 100%, 92%, 40%, 100%, and 92%, respectively.
  • The median overall survival of patients with CT-detected bladder invasion versus cystoscopy-confirmed invasion was 13 months versus 4 months, respectively (P = 0.007).
  • CONCLUSIONS: Our results show that for cervical cancer, cystoscopy is not required in patients without any bladder invasion on CT scan.
  • In the revised FIGO staging system, use of cystoscopy may be limited to patients having suspicious bladder invasion on CT scan.
  • [MeSH-major] Adenocarcinoma / radiography. Carcinoma, Squamous Cell / radiography. Cystoscopy. Tomography, X-Ray Computed. Urinary Bladder Neoplasms / diagnosis. Uterine Cervical Neoplasms / radiography


62. Kim SS, Choi YD, Nam JH, Kwon DD, Juhng SW, Choi C: Cytologic features of primary signet ring cell carcinoma of the bladder: a case report. Acta Cytol; 2009 May-Jun;53(3):309-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of primary signet ring cell carcinoma of the bladder: a case report.
  • BACKGROUND: Signet ring cell carcinoma is a very rare subtype of adenocarcinoma of the urinary bladder.
  • Urine cytology is a useful method for screening and followup of urinary bladder carcinoma.
  • Cystoscopy revealed very large masses in the anterior and posterior wall of the bladder.
  • Bladder washings, urine cytology and biopsy demonstrated characteristic signet ring cells without foci of urothelial carcinoma or other lesions.
  • CONCLUSION: Signet ring cell carcinoma of the urinary bladder can be diagnosed by urinary cytology and confirmed by cystoscopic biopsy.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Ascites / pathology. Biopsy. Fatal Outcome. Female. Hematuria / etiology. Hematuria / pathology. Humans. Therapeutic Irrigation. Tomography, X-Ray Computed. Urinalysis. Urinary Bladder / radiography

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534273.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Yoshida K, Yamazaki H, Takenaka T, Kotsuma T, Yoshida M, Furuya S, Tanaka E, Uegaki T, Kuriyama K, Matsumoto H, Yamada S, Ban C: A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer. Int J Radiat Oncol Biol Phys; 2010 Jul 1;77(3):765-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer.
  • PURPOSE: To investigate the feasibility of our novel image-based high-dose-rate interstitial brachytherapy (HDR-ISBT) for uterine cervical cancer, we evaluated the dose-volume histogram (DVH) according to the recommendations of the Gynecological GEC-ESTRO Working Group for image-based intracavitary brachytherapy (ICBT).
  • METHODS AND MATERIALS: Between June 2005 and June 2007, 18 previously untreated cervical cancer patients were enrolled.
  • DVHs of the high-risk clinical target volume (HR CTV), intermediate-risk CTV (IR CTV), and the bladder and rectum were calculated.
  • The D(2cc) of the bladder was 62 Gy (range, 51.4-89) and of the rectum was 65.9 Gy (range, 48.9-76).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Ambulatory Care / methods. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Middle Aged. Radiotherapy Dosage. Rectum / radiation effects. Statistics, Nonparametric. Tumor Burden. Urinary Bladder / radiation effects


64. Shanks JH, Iczkowski KA: Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology; 2009 Jun;54(7):885-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics.
  • Conventional urothelial carcinoma accounts for most carcinomas of the urinary tract lining.
  • Pure squamous carcinoma or adenocarcinoma (the latter in particular) can be difficult to distinguish from contiguous or metastatic spread.
  • Sarcomatoid carcinoma and its differential diagnosis with other spindle cell lesions of urinary tract will be covered in a separate review.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Adenoma / diagnosis. Adenoma / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Cell Differentiation. Cystitis / diagnosis. Cystitis / pathology. Diagnosis, Differential. Giant Cell Tumors / diagnosis. Giant Cell Tumors / pathology. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology. Neoplasms, Squamous Cell / diagnosis. Neoplasms, Squamous Cell / pathology. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / pathology. Radiation Injuries / diagnosis. Radiation Injuries / pathology. Urothelium / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178589.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 152
  •  go-up   go-down


65. Domanowska E, Jozwicki W, Domaniewski J, Golda R, Skok Z, Wiśniewska H, Sujkowska R, Wolski Z, Jozwicka G: Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Hum Pathol; 2007 May;38(5):741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize.
  • Few published studies have addressed the correlation between multidirectional differentiation in muscle-invasive bladder cancer and its ability to metastasize.
  • We examined cystectomy specimens from 93 bladder tumors and 1085 lymph nodes.
  • In this study, urothelial cell carcinomas (UCCs) with divergent differentiation, excluding pure divergent patterns such as squamous cell carcinoma and adenocarcinoma that tend toward a distinct biologic behavior, were subjected to histopathologic estimation.
  • [MeSH-major] Cell Differentiation. Muscles / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306328.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Datta C, Bhattacharyya S, Bhattacharya S, Ghosh S: Primary adenocarcinoma of bladder--A case report. J Indian Med Assoc; 2006 Jun;104(6):338-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of bladder--A case report.
  • Ultrasonography depicted an echogenic mass on bladder wall, where prostate showed normal echo characters.
  • Cystoscopy revealed a large papillary growth involving lateral wall, neck of the urinary bladder and prostatic urethra.
  • Punched biopsy showed features of adenocarcinoma.
  • Radical cystectomy was performed and it was reported as a case of primary adenocarcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058556.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


67. Siefker-Radtke A: Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther; 2006 Dec;6(12):1715-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The urachal ligament is an embryologic remnant connecting the dome of the bladder to the umbilicus via the ligamentum commune.
  • Patients usually present with hematuria and upon imaging, have evidence of a cystic or solid structure in the bladder dome or in the bladder midline.
  • If a biopsy confirms adenocarcinoma, these tumors should be considered an urachal cancer until proven otherwise.
  • Unfortunately, there are many patients who present with metastatic disease that currently is not likely to be curable.
  • [MeSH-major] Adenocarcinoma / therapy. Cystectomy / methods. Urachus / pathology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Cisplatin / administration & dosage. Clinical Trials as Topic. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Hematuria / etiology. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Risk Factors. Umbilicus / surgery. Urachal Cyst / pathology. Urachal Cyst / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181485.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 29
  •  go-up   go-down


68. Lauretti S, Mosca A, D'Alfonso V, Donadio D, Brisciani A: Primitive mucinous adenocarcinoma of the bladder. A case report. Arch Ital Urol Androl; 2006 Mar;78(1):32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive mucinous adenocarcinoma of the bladder. A case report.
  • Primary mucing-producing adenocarcinoma of the bladder is a rare, highly malignant tumor.
  • It is classified as the third most frequent histologic type of bladder carcinoma characterized by a poor response to radiotherapy and/or chemotherapy.
  • Only surgery seems to offer the best approach to this unusual cancer The authors report the pathological findings and the clinical course of a 45-years old man with a primary mucin-secreting adenocarcinoma of the bladder.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752888.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


69. Ide H, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J, Oya M: The predictors of local recurrence after radical cystectomy in patients with invasive bladder cancer. Jpn J Clin Oncol; 2008 May;38(5):360-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The predictors of local recurrence after radical cystectomy in patients with invasive bladder cancer.
  • METHODS: We identified a study population of 146 consecutive patients treated surgically for invasive bladder cancer at our institution between 1987 and 2003.
  • The presence of concomitant adenocarcinoma component, pathological nodal involvement and the number of retrieved lymph nodes were independent predictors of local recurrence.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Cystectomy. Lymph Nodes / pathology. Neoplasm Recurrence, Local / prevention & control. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors. Vascular Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18490370.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Gobet R, Weber D, Renzulli P, Kellenberger C: Long-term follow up (37-69 years) of patients with bladder exstrophy treated with ureterosigmoidostomy: uro-nephrological outcome. J Pediatr Urol; 2009 Jun;5(3):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow up (37-69 years) of patients with bladder exstrophy treated with ureterosigmoidostomy: uro-nephrological outcome.
  • OBJECTIVE: To describe the urological and nephrological long-term outcome of patients born with classical bladder exstrophy treated with bilateral ureterosigmoidostomies in early childhood.
  • PATIENTS AND METHOD: Out of 42 patients born with bladder exstrophy in Switzerland between 1937 and 1968, 25 participated in this study; seven had died, seven were lost to follow up and three refused consent.
  • All others had different forms of urinary diversions.
  • One patient suffered from adenocarcinoma of the colon, five had benign colonic polyps, one urethral papillary carcinoma and 18 no evidence of tumor.
  • [MeSH-major] Bladder Exstrophy / epidemiology. Bladder Exstrophy / surgery. Postoperative Complications / epidemiology. Ureterostomy. Urinary Diversion
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adolescent. Adult. Aged. Carcinoma, Papillary / epidemiology. Child. Child, Preschool. Colonic Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Urinary Incontinence / epidemiology. Urination. Urolithiasis / epidemiology

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136304.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Schildhaus HU, Mikuz G, Fisang C, Steiner S, Büttner R, Wardelmann E: [Malignant mixed Müllerian tumor of the urinary bladder]. Pathologe; 2008 Sep;29(5):375-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant mixed Müllerian tumor of the urinary bladder].
  • True mixed epithelial-mesenchymal tumors of the urinary bladder are exceedingly rare, and only two vesical adenosarcomas have been reported to date.
  • These tumors originated from bladder endometriosis, and malignant transformation of endometriosis has been described, with endometrioid and clear-cell carcinomas being the most common malignancies.
  • We report an unusual case of a malignant mixed Müllerian tumor with heterologous rhabdomyoblastic differentiation, which originated in the urinary bladder of a postmenopausal woman.
  • To the best of our knowledge, such a neoplasm has not yet been reported in the literature.
  • [MeSH-major] Endometriosis / pathology. Mixed Tumor, Mullerian / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Aged. Carcinosarcoma / pathology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Female. Humans. Treatment Outcome. Uterine Neoplasms / pathology


72. Lane Z, Hansel DE, Epstein JI: Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol; 2008 Sep;32(9):1322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
  • Adenocarcinomas of the bladder are rare, with the diagnosis dependent on exclusion of secondary involvement by direct extension or metastatic spread from other sites.
  • The recent description of an unusual form of urothelial-type mucinous prostatic adenocarcinoma raises a novel differential diagnosis between adenocarcinomas of the prostate and bladder, and investigation into the utility of classic prostatic immunohistochemical antigens in bladder adenocarcinoma is warranted.
  • We identified 37 primary infiltrating adenocarcinomas of the bladder, which included signet ring cell carcinomas (n=11), urachal adenocarcinomas (n=5), and enteric adenocarcinoma (n=21).
  • Also included for comparison were 3 cases, each of bladder villous adenomas and bladder adenocarcinoma in situ.
  • In contrast, a minority of bladder adenocarcinomas was labeled with the prostate antigens P501S and PSMA.
  • P501S showed moderate diffuse cytoplasmic staining in 4/37 cases (11%), including 3 enteric-type adenocarcinomas and 1 mucinous adenocarcinoma.
  • Additionally, 1 case of adenocarcinoma in situ demonstrated diffuse cytoplasmic staining for P501S.
  • The granular perinuclear staining pattern of P501S typically seen in prostatic adenocarcinoma was absent in all cases of bladder adenocarcinoma.
  • PSMA showed diffuse cytoplasmic staining in 4/37 (11%) infiltrating adenocarcinomas (including 1 signet ring carcinoma and 3 enteric-type adenocarcinomas), and in 1 case of adenocarcinoma in situ.
  • Membranous PSMA staining was evident in an additional 3 tumors, 1 urachal mucinous adenocarcinoma, 1 nonurachal mucinous and signet ring cell adenocarcinoma, and 1 nonurachal villous adenoma.
  • In conclusion, although all cases of bladder adenocarcinoma examined were negative for PSA and PSAP, the surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenocarcinomas.
  • The lack of granular perinuclear staining for P501S and the absence of membranous PSMA staining both favor a bladder adenocarcinoma, although rare cases of villous adenoma and adenocarcinoma did show PSMA membranous staining indistinguishable from that seen in prostate cancer.
  • Although the novel antigens P501S and PSMA are fairly specific and more sensitive in the differential diagnosis of prostate and urothelial carcinoma, care must be taken when adenocarcinomas of the bladder are considered within this differential diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Antigens, Neoplasm / biosynthesis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Acid Phosphatase. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Membrane Proteins / biosynthesis. Prostate-Specific Antigen / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Protein Tyrosine Phosphatases / biosynthesis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670358.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Membrane Proteins; 0 / prostein; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


73. Sugimori K, Kobayashi K, Hayashi M, Sakai N, Sasaki M, Koshino Y: Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study. Neuropathology; 2005 Mar;25(1):89-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study.
  • We report a 73-year-old male patient with leptomeningeal metastasis from urinary bladder adenocarcinoma.
  • Meningeal carcinomatosis was detected 5 days before his death, but the primary site of the malignant tumor could not be determined.
  • Necropsy revealed leptomeningeal infiltration of many adenocarcinoma cells that covered the cerebrum.
  • Meningeal carcinomatosis from urinary bladder adenocarcinoma is extremely rare and up-regulation of the adhesion molecules in the meningeal adenocarcinoma was confirmed.
  • [MeSH-major] Adenocarcinoma / secondary. Meningeal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15822823.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Vascular Cell Adhesion Molecule-1; 68238-35-7 / Keratins
  •  go-up   go-down


74. Mazzucchelli R, Barbisan F, Santinelli A, Scarpelli M, Galosi AB, Lopez-Beltran A, Cheng L, Kirkali Z, Montironi R: Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer. Urology; 2009 Aug;74(2):385-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer.
  • OBJECTIVES: To ascertain which variables of bladder urothelial carcinoma (UC) might be useful in predicting either UC involving the prostate (UCP) or incidental prostate adenocarcinoma in radical cystoprostatectomy specimens.
  • METHODS: The bladder and whole-mount prostate sections of 248 radical cystoprostatectomy specimens were reviewed.
  • Stepwise discriminant analysis was used to predict UCP or incidental prostate adenocarcinoma.
  • UC originated from the prostatic urethra and periurethral ducts in 78 (31.45%), and isolated direct extension of UC from the bladder was present in 16 patients (6.45%).
  • The periurethral ducts coexisted with direct extension of bladder UC in 11 patients (4.4%).
  • Prostate adenocarcinoma was identified in 123 patients (49.6%).
  • The tumor was in the trigone and bladder neck in 160 patients (64.5%).
  • Stepwise discriminant analysis selected 3 variables of bladder UC (previous recurrence and location and number of foci) and correctly predicted the group in 72.2% of patients without and with UCP.
  • Discriminant analysis selected 2 variables of bladder UC (focality and previous recurrence) and correctly predicted the group in 57.7% of patients without and with prostate adenocarcinoma.
  • CONCLUSIONS: Our approach can identify bladder UC variables that could guide urologists in the selection of the most appropriate surgical procedure.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Prostatectomy. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Multiple Primary / diagnosis


75. Ibele AR, Koplin SA, Slaughenhoupt BL, Kryger JV, Friedl A, Lund DP: Colonic adenocarcinoma in a 13-year-old with cystic fibrosis. J Pediatr Surg; 2007 Oct;42(10):E1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenocarcinoma in a 13-year-old with cystic fibrosis.
  • Here we report a case of colonic adenocarcinoma presenting as pneumaturia in a 13-year-old patient with cystic fibrosis.
  • [MeSH-major] Adenocarcinoma / complications. Cecal Neoplasms / complications. Cystic Fibrosis / complications
  • [MeSH-minor] Adolescent. Air. Anastomosis, Surgical. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Intestinal Fistula / etiology. Intestinal Fistula / surgery. Intestinal Fistula / urine. Leucovorin / administration & dosage. Male. Organoplatinum Compounds / administration & dosage. Urinary Bladder Fistula / etiology. Urinary Bladder Fistula / surgery. Urinary Bladder Fistula / urine. Urine

  • Genetic Alliance. consumer health - BabysFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923181.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


76. Fröhlich C, Albrechtsen R, Dyrskjøt L, Rudkjaer L, Ørntoft TF, Wewer UM: Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res; 2006 Dec 15;12(24):7359-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular profiling of ADAM12 in human bladder cancer.
  • PURPOSE: We have previously found ADAM12, a disintegrin and metalloprotease, to be an interesting biomarker for breast cancer.
  • The purpose of this study was to determine the gene and protein expression profiles of ADAM12 in different grades and stages of bladder cancer.
  • EXPERIMENTAL DESIGN: ADAM12 gene expression was evaluated in tumors from 96 patients with bladder cancer using a customized Affymetrix GeneChip.
  • Gene expression in bladder cancer was validated using reverse transcription-PCR, quantitative PCR, and in situ hybridization.
  • Protein expression was evaluated by immunohistochemical staining on tissue arrays of bladder cancers.
  • The presence and relative amount of ADAM12 in the urine of cancer patients were determined by Western blotting and densitometric measurements, respectively.
  • RESULTS: ADAM12 mRNA expression was significantly up-regulated in bladder cancer, as determined by microarray analysis, and the level of ADAM12 mRNA correlated with disease stage.
  • Finally, ADAM12 could be detected in the urine by Western blotting; ADAM12 was present in higher levels in the urine from patients with bladder cancer compared with urine from healthy individuals.
  • Significantly, following removal of tumor by surgery, in most bladder cancer cases examined, the level of ADAM12 in the urine decreased and, upon recurrence of tumor, increased.
  • CONCLUSIONS: ADAM12 is a promising biomarker of bladder cancer.
  • [MeSH-major] ADAM Proteins / metabolism. Carcinoma, Transitional Cell / metabolism. Gene Expression Profiling / methods. Membrane Proteins / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma / urine. Adult. Aged. Aged, 80 and over. Amyloid Precursor Protein Secretases / metabolism. Animals. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / urine. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Mammary Neoplasms, Experimental / metabolism. Mammary Neoplasms, Experimental / pathology. Mice. Middle Aged. Mucous Membrane / metabolism. Neoplasm Recurrence, Local / urine. Neoplasm Staging

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189408.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.24.- / ADAM 12 protein; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM8 protein, human; EC 3.4.24.81 / ADAM10 protein, human
  •  go-up   go-down


77. Yenilmez A, Donmez T, Acikalin MF, Kale M: Adenonocarcinoma of the urinary bladder mimicking simple ureterocele: a case report. Int Urol Nephrol; 2007;39(2):465-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenonocarcinoma of the urinary bladder mimicking simple ureterocele: a case report.
  • We report a case of adenocarcinoma of the urinary bladder, mimicking simple ureterocele in a 55-year-old man, presenting irritative bladder symptoms.
  • Transurethral biopsy of the lesion was performed and pathological examination revealed a muscle-invasive adenocarcinoma.
  • The patient underwent radical cystectomy and urinary diversion.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ureterocele / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Can Assoc Radiol. 1972 Dec;23 (4):284-6 [4646901.001]
  • [Cites] J Urol. 1974 Jan;111(1):36-7 [4813551.001]
  • [Cites] Br J Urol. 1987 Sep;60(3):271-2 [3676678.001]
  • [Cites] J Urol. 1977 May;117(5):557-61 [870705.001]
  • [Cites] Urology. 1984 Aug;24(2):175-7 [6464253.001]
  • [Cites] Urology. 1981 Jul;18(1):91 [7257050.001]
  • (PMID = 17171419.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


78. Castillo CM, Ha CY, Gater DR, Grob BM, Klausner AP: Prophylactic radical cystectomy for the management of keratinizing squamous metaplasia of the bladder in a man with tetraplegia. J Spinal Cord Med; 2007;30(4):389-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic radical cystectomy for the management of keratinizing squamous metaplasia of the bladder in a man with tetraplegia.
  • BACKGROUND/OBJECTIVE: To report a case of keratinizing squamous metaplasia of the bladder treated with radical cystectomy.
  • METHODS: Keratinizing squamous metaplasia of the bladder is a rare entity that can result from chronic irritative stimuli involving the bladder.
  • A case report is presented describing the diagnosis and management of keratinizing squamous metaplasia of the bladder in a tetraplegic man with a chronic indwelling urinary catheter.
  • Final pathology revealed focal erosion and diffuse keratinizing squamous metaplasia of the bladder with prostatic adenocarcinoma as an incidental finding.
  • CONCLUSIONS: Patients with spinal cord injury who use indwelling catheters for bladder management are at higher risk of developing keratinizing squamous metaplasia.
  • An interdisciplinary approach is recommended before consideration of bladder resection.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / surgery. Cystectomy / methods. Quadriplegia / complications. Urinary Bladder Neoplasms / etiology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Pathol Microbiol. 1994 Dec;37 Suppl:S39-40 [8613170.001]
  • [Cites] Arch Phys Med Rehabil. 1995 Aug;76(8):758-62 [7632132.001]
  • [Cites] J Urol. 1997 Jun;157(6):2115 [9146594.001]
  • [Cites] SCI Nurs. 1997 Sep;14(3):87-95 [9355615.001]
  • [Cites] J Clin Pathol. 1998 Aug;51(8):583-7 [9828815.001]
  • [Cites] Urology. 1999 Feb;53(2):292-7 [9933042.001]
  • [Cites] World J Urol. 1999 Aug;17(4):211-8 [10460403.001]
  • [Cites] Urol Clin North Am. 2005 May;32(2):207-16 [15862618.001]
  • [Cites] J Urol. 2005 Nov;174(5):1729-36 [16217273.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):883-91 [16819332.001]
  • [Cites] Int Urol Nephrol. 1999;31(4):457-61 [10668940.001]
  • [Cites] Spinal Cord. 2001 Nov;39(11):568-70 [11641805.001]
  • [Cites] BJU Int. 2002 Sep;90(4):386-90 [12175394.001]
  • [Cites] Eur Urol. 2002 Oct;42(4):350-5 [12361900.001]
  • [Cites] Eur Urol. 2002 Nov;42(5):469-74 [12429156.001]
  • [Cites] J Spinal Cord Med. 2003 Winter;26(4):335-8 [14992333.001]
  • [Cites] Qual Life Res. 2004 Feb;13(1):97-110 [15058792.001]
  • [Cites] Rehabil Nurs. 2004 Jul-Aug;29(4):122-6 [15222093.001]
  • [Cites] J Urol. 1967 Aug;98(2):206-8 [6046997.001]
  • [Cites] Urology. 1975 Dec;6(6):759-61 [1202729.001]
  • [Cites] J Urol. 1977 Dec;118(6):967-71 [926277.001]
  • [Cites] J Urol. 1979 Sep;122(3):317-21 [470001.001]
  • [Cites] S Afr Med J. 1980 Nov 1;58(18):725-8 [7423317.001]
  • [Cites] J Urol. 1985 Jun;133(6):1034-5 [3999203.001]
  • [Cites] J Urol. 1997 Jun;157(6):2112-4 [9146593.001]
  • (PMID = 17853664.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2031939
  •  go-up   go-down


79. Prieto MC, Matousek P, Towrie M, Parker AW, Wright M, Ritchie AW, Stone N: Use of picosecond Kerr-gated Raman spectroscopy to suppress signals from both surface and deep layers in bladder and prostate tissue. J Biomed Opt; 2005 Jul-Aug;10(4):44006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of picosecond Kerr-gated Raman spectroscopy to suppress signals from both surface and deep layers in bladder and prostate tissue.
  • Prostate samples for this study were obtained by taking a chip at the transurethral resection of the prostate (TURP), and bladder samples from a biopsy taken at transurethral resection of bladder tumor (TURBT) and TURP.
  • Spectra obtained through the bladder and prostate gland tissue, at different time delays after the laser pulse, clearly show change in the spectra as depth profiling occurs, eventually showing signals from the uric acid cell and urea cell, respectively.
  • We show for the first time, using this novel technique, that we are able to obtain spectra from different depths through both the prostate gland and the bladder.
  • This has major implications in the future of Raman spectroscopy as a tool for diagnosis.
  • With the help of Raman spectroscopy and Kerr gating, it may be possible to pick up the spectral differences from a small focus of adenocarcinoma of the prostate gland in an otherwise benign gland, and also stage the bladder cancers by assessing the base of the tumor post resection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Prostatic Neoplasms / chemistry. Prostatic Neoplasms / diagnosis. Spectrum Analysis, Raman / methods. Urinary Bladder Neoplasms / chemistry. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Algorithms. Artifacts. Humans. Male. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178640.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


80. Marlin ES, Hyams ES, Dulabon L, Shah O: Metastatic esophageal adenocarcinoma to the prostate presenting with bilateral ureteral obstruction. Can J Urol; 2010 Feb;17(1):5035-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic esophageal adenocarcinoma to the prostate presenting with bilateral ureteral obstruction.
  • Carcinoma metastatic to the prostate occurs rarely and is most commonly associated with malignant bladder neoplasms.
  • We present the case of a 73-year-old male with a history of gastroesophageal adenocarcinoma and clinically symptomatic benign prostatic hyperplasia who underwent photoselective vaporization of the prostate and presented several months later with gross hematuria, intermittent urinary retention and bilateral ureteral obstruction causing acute renal failure.
  • After relieving the ureteral obstruction, subsequent transurethral resection of the prostate revealed locally invasive metastatic esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Prostatic Neoplasms / secondary. Ureteral Obstruction / etiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Neoplasm Invasiveness. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156389.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


81. Jasperson KW, Blazer KR, Lowstuter K, Weitzel JN: Working through a diagnostic challenge: colonic polyposis, Amsterdam criteria, and a mismatch repair mutation. Fam Cancer; 2008;7(4):281-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two most common causes of hereditary colorectal cancer are Lynch syndrome and familial adenomatous polyposis (FAP).
  • The phenotype of Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is differentiated in part from FAP by the lack of profuse colonic polyposis.
  • Here we describe a proband who presented with greater than 50 adenomatous colonic polyps prior to developing cancer of the colon and urinary bladder, and a family history that fulfills the Amsterdam criteria.
  • Germline analyses of APC and MYH in the proband did not reveal any mutations.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenomatous Polyposis Coli / complications. Colonic Neoplasms / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. DNA-Binding Proteins
  • [MeSH-minor] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / genetics. Female. Genes, APC. Germ-Line Mutation. Humans. Middle Aged. Neoplasms, Multiple Primary / genetics. Pedigree. Phenotype. Urinary Bladder Neoplasms / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1822-7 [12135043.001]
  • [Cites] Clin Genet. 1998 Oct;54(4):368-70 [9831355.001]
  • [Cites] Gut. 1997 Aug;41(2):235-8 [9301504.001]
  • [Cites] Gene. 2001 Jul 11;272(1-2):301-13 [11470537.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):42-8 [14699485.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Hum Mutat. 2004 Mar;23(3):285 [14974087.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):807-14 [16557584.001]
  • [Cites] Int J Colorectal Dis. 2006 Jan;21(1):79-83 [16676398.001]
  • [Cites] J Med Genet. 1999 Oct;36(10 ):790-3 [10528862.001]
  • [Cites] Dis Colon Rectum. 1991 May;34(5):424-5 [2022152.001]
  • [Cites] Int J Colorectal Dis. 2006 Dec;21(8):847-50 [16525781.001]
  • [Cites] J Bacteriol. 1994 Sep;176(17):5393-400 [8071216.001]
  • [Cites] Hum Genet. 2006 Mar;119(1-2):206-11 [16408224.001]
  • [Cites] Gut. 2003 Jun;52(6):898-9 [12740349.001]
  • [Cites] Fam Cancer. 2007;6(1):43-51 [17039270.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Oct;3(10):1022-8 [16234049.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11135-42 [11801590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5908-13 [12732731.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):643-8 [11807791.001]
  • (PMID = 18176851.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000043; United States / NCI NIH HHS / CA / R25 CA085771; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCI NIH HHS / CA / R25 CA85771
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein
  •  go-up   go-down


82. Sanli O, Acar O, Celtik M, Oktar T, Kilicaraslan I, Ozcan F, Tunc M, Esen T: Should prostate cancer status be determined in patients undergoing radical cystoprostatectomy? Urol Int; 2006;77(4):307-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should prostate cancer status be determined in patients undergoing radical cystoprostatectomy?
  • INTRODUCTION: We estimate the frequency of prostate cancers detected incidentally in radical cystoprostatectomy specimens and discuss whether the prostate cancer status should be determined in patients undergoing radical cystoprostatectomy.
  • MATERIALS AND METHODS: A total of 97 radical cystoprostatectomies without evidence of prostate cancer on digital rectal examination were performed for transitional cell carcinomas of the bladder between January 2001 and May 2004.
  • RESULTS: The overall incidence of prostate cancer detected in radical cystoprostatectomy specimens was 21.6% (21/97 specimens).
  • CONCLUSIONS: Despite the high prevalence of incidental prostate carcinomas among patients with bladder cancer undergoing cystoprostatectomy, the vast majority of the cancers are organ confined.
  • However, the prostate cancer status should be determined on the basis of digital rectal examination and prostate-specific antigen in patients undergoing radical cystoprostatectomy - especially if prostate-sparing cystectomy is planned.
  • [MeSH-major] Adenocarcinoma / pathology. Cystectomy. Prostatectomy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Diagnosis, Differential. Follow-Up Studies. Humans. Incidence. Intraoperative Period. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17135779.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


83. Wilhelm TJ, Knoll T, Weisser G, Grobholz R, Köhrmann KU, Post S: Urothelial carcinoma of the ureter, giant rectal stone and sigmoid carcinoma 55 years after ureterosigmoidostomy. Scand J Urol Nephrol; 2006;40(2):172-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a unique accumulation of complications 55 years after ureterosigmoidostomy for bladder exstrophy and discuss possible implications for follow-up strategies.
  • [MeSH-major] Calculi / pathology. Colonic Neoplasms / pathology. Rectal Diseases / pathology. Ureteral Neoplasms / pathology. Urinary Bladder / abnormalities. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Humans. Ileum / surgery. Male. Middle Aged. Reconstructive Surgical Procedures. Sigmoidoscopy. Tomography, X-Ray Computed. Ureterostomy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608820.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


84. Popov Z, Stavridis A, Lekovski Lj, Penev M, Dohcev S, Stankov O, Petrovski D, Saidi S, Kuzmanoski M, Stavridis S, Mickovski A, Banev S, Zografski G, Janculev J, Ivanovski O, Georgiev V: Urinary diversion: 30 years experience of a single centre in Republic of Macedonia. Acta Chir Iugosl; 2007;54(4):49-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary diversion: 30 years experience of a single centre in Republic of Macedonia.
  • OBJECTIVES: The aim of this report is to present our 30 years experience with various types of urinary diversions, in particular the Bricker and Studer techniques for the management of muscle invasive bladder cancer at our institution.
  • MATERIAL AND METHODS: Between 1977 and 2007, 186 male and 15 female patients underwent combined radical cystectomy, pelvic lymphadenectomy and urinary diversion.
  • RESULTS: Two main types of urinary diversion were performed: the ileal conduit diversion using a technique previously described by Bricker and the ileal neobladder diversion using a technique previously described by a Studer.
  • Histopathologically, transitional cell carcinoma was the most common tumor cell type (93,7%), followed by difuse papilomatosis (5.5%) and adenocarcinoma (0.7%).
  • CONCLUSION: We show that our results with urinary diversion are promising in patients requiring radical cystoprostatectomy.
  • The two methods preferred in our institution offer a sufficient protection of the upper urinary tract with a low complication rate, good voiding function and continence.
  • [MeSH-major] Urinary Diversion
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Cystectomy. Female. Humans. Male. Middle Aged. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595229.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


85. Wood RW, Baggs RB, Schwarz EM, Messing EM: Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate. Urology; 2006 Jun;67(6):1324-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate.
  • OBJECTIVES: To characterize the voiding function in a transgenic adenocarcinoma of murine prostate (TRAMP) mouse of advanced age, because it might provide a useful model of slow-onset bladder outlet obstruction.
  • Spontaneous death from urinary outlet obstruction occurs in the TRAMP mouse.
  • Postmortem histologic examination revealed gross enlargement of the prostate, a suburethral tumor, dilation of the lumen of the urethra, and proteinaceous debris in the urethra and bladder.
  • This transgenic mouse strain may provide a model of slow-onset outlet obstruction that is more representative of bladder outlet obstruction caused by benign prostatic hyperplasia than is the obstruction produced by urethral ligation.
  • [MeSH-major] Adenocarcinoma / physiopathology. Prostatic Neoplasms / physiopathology. Urodynamics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765198.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 057679
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Chan ES, Ng CF, Chui KL, Lo KL, Hou SM, Yip SK: Novel approach of laparoscopic transperitoneal en bloc resection of urachal tumor and umbilectomy with a comparison of various techniques. J Laparoendosc Adv Surg Tech A; 2009 Jun;19(3):423-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urachal carcinoma is a rare cancer that accounts for less than 1% of all bladder cancers.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy / methods. Umbilicus / surgery. Urachus / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19405800.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Raspollini MR, Nesi G, Baroni G, Girardi LR, Taddei GL: Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder. Appl Immunohistochem Mol Morphol; 2005 Dec;13(4):358-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder.
  • Distinguishing between primary adenocarcinomas and secondary colonic adenocarcinomas of the urinary bladder is often difficult because they appear morphologically similar but invariably require different treatment strategies.
  • The aim of the study was to define the utility of a limited immunohistochemical panel consisting of CDX-2, cytokeratins 7 (CK7) and 20 (CK20), and carcinoembryonic antigen (CEA) in differentiating primary from secondary bladder adenocarcinomas.
  • Formalin-fixed, paraffin-embedded tissues from 8 primary bladder adenocarcinomas and 23 colorectal adenocarcinomas involving the bladder were included in the study.
  • The majority (87.5%) of primary bladder adenocarcinomas were CDX-2 negative, and only one case of primary bladder adenocarcinoma was positive, while CDX-2 was strongly expressed in the nucleus of all cases of secondary (colonic) bladder tumor (P < 0.0005).
  • Five cases (62.5%) of primary bladder adenocarcinoma and one case (4.3%) of secondary bladder tumor showed positive staining for CK7 (P = 0.002), whereas CK20 showed positive staining in five cases (62.5%) of primary bladder adenocarcinoma and in all the secondary bladder tumors (P = 0.012).
  • All 23 secondary bladder tumors and 7 primary bladder adenocarcinomas (87.5%) expressed CEA (P = 0.25).
  • These data demonstrate that a restricted immunohistochemical panel consisting of CDX-2, CK7, CK20, and CEA may be of use in differentiating primary bladder adenocarcinoma from secondary adenocarcinoma of colorectal origin.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280666.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Homeodomain Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein; 68238-35-7 / Keratins
  •  go-up   go-down


88. Kato M, Onishi T, Hoshina A, Yabana T: Successful treatment with paclitaxel/carboplatin chemotherapy in advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125. Urol Int; 2010;84(1):116-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with paclitaxel/carboplatin chemotherapy in advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125.
  • Primary adenocarcinoma of the urinary tract producing tumor markers is extremely rare.
  • We report 2 cases of advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125), which were completely resected after induction chemotherapy with paclitaxel and carboplatin.
  • Patient 1 was a 72-year-old woman with adenocarcinoma of the right renal pelvis and ureter.
  • Patient 2 was a 73-year-old woman with adenocarcinoma of the bladder.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / biosynthesis. CA-19-9 Antigen / biosynthesis. Carboplatin / administration & dosage. Carcinoembryonic Antigen / biosynthesis. Paclitaxel / administration & dosage. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20173382.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


89. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of bladder tumours in a single institution in Malaysia.
  • OBJECTIVE: To determine the clinicopathological features of bladder tumours encountered over a five year period in Universiti Kebangsaan Malaysia Medical Centre.
  • METHODS: Medical records of bladder tumour cases from 2005 till 2009 were retrospectively reviewed and tabulated.
  • The main histopathology was transitional cell carcinoma (TCC) (90.4%), followed by adenocarcinoma (6%), squamous cell carcinoma (1.2%), leiomyoma (1.2%) and myeloid sarcoma (1.2%).
  • Mean survival of patients with muscle invasive cancer was 33+/-5 months.
  • By the end of the study, 18.1% of patients had died of their cancer.
  • CONCLUSION: The incidence of bladder tumours is highest among the Chinese.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


90. Zebentout O, Apardian R, Beaulieu L, Harel F, Martin AG, Vigneault E: [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience]. Cancer Radiother; 2010 Jun;14(3):183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
  • [Transliterated title] Evolution clinique des patients atteints d'un cancer prostatique de risque intermédiaire traités par implants permanents d'iode-125 : l'expérience de l'Hôtel-Dieu de Québec.
  • PURPOSE: To describe the biochemical failure-free survival (BFFS), GU toxicity and erectile dysfunction in intermediate risk prostate cancer treated with iodine 125 monotherapy (I125).
  • PATIENTS AND METHODS: Between October 1994 and October 2007, 1282 patients were treated with I125 at the Hotel Dieu de Quebec.
  • Two hundred patients were intermediate risk prostate cancer.
  • Acute and late GU toxicity was described using the International Prostate Symptoms Score (IPSS) as well as with the rate of bladder catheter.
  • Acute urinary retention with bladder catheter occurred in 10.9% of patients.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Iodine Radioisotopes / therapeutic use. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20418145.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Iodine Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


91. Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, el-Baz MA: Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol; 2008 Jul;180(1):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later.
  • PURPOSE: We performed a critical analysis of the results of radical cystectomy for invasive bladder carcinoma treated at 1 center.
  • MATERIALS AND METHODS: Between 1970 and 2000, 2,090 men and 630 women with invasive bladder cancer were treated with 1-stage radical cystectomy and urinary diversion.
  • Squamous tumors accounted for 49.4% of cases, transitional cell carcinoma for 36.4% and adenocarcinoma for 9.6%.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2008 Jul;180(1):12-3 [18485379.001]
  • (PMID = 18485392.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP Jr: Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol; 2007 Nov-Dec;25(6):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Prostate capsule sparing cystectomy has been performed in conjunction with orthotopic diversion to preserve sexual function and improve urinary control.
  • Because concerns remain regarding incomplete surgical resection, we evaluated the risk of urothelial and prostate cancer in a series of patients undergoing radical cystoprostatectomy.
  • METHODS: A total of 35 men undergoing radical cystoprostatectomy (August 2003-August 2005) had separate submission of the prostate peripheral zone/capsule from the prostate adenoma and bladder after surgery.
  • These specimens were evaluated for bladder and prostate cancer grade, stage, and largest diameter of prostate cancer.
  • RESULTS: Of patients, 57% had cancer involving the prostate at radical cystoprostatectomy.
  • Prostate adenocarcinoma was evident in 16 of 35 (47%) patients, with a majority involving the prostate peripheral zone/capsule (43%).
  • There were 4 patients (11%) who had clinically significant prostate cancer (Gleason sum >6 or tumor volume >0.5 cm(3)).
  • Patients with prostate cancer were significantly older than patients without prostate cancer (P = 0.01).
  • CONCLUSIONS: No clinical variable can confidently predict patients with prostate cancer involving the prostate.
  • Because a majority of patients undergoing radical cystoprostatectomy have cancer involving their prostate, preoperative evaluation with prostatic urethral and prostate biopsy may be useful to guide patient selection for prostate capsule sparing cystectomy.
  • [MeSH-major] Cystectomy / methods. Prostate / pathology. Prostatectomy / methods. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047952.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Sasaki M, Kobayashi T, Ono K, Sugano O, Sasao S, Hoshi S: [Small cell carcinoma of the prostate: a case report]. Hinyokika Kiyo; 2006 Sep;52(9):719-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 79-year-old man was admitted to our department with a chief complaint of urinary incontinence.
  • We performed a prostate biopsy and histological examinations indicated poorly differentiated adenocarcinoma with a Gleason score of 5+5=10.
  • A computed tomographic (CT) scan revealed a prostatic tumor invading the bladder, seminal vesicle and rectum.
  • He was diagnosed with a stage T4N1M0 adenocarcinoma of the prostate.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040059.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


94. Paras FA Jr, Maclennan GT: Urachal adenocarcinoma. J Urol; 2008 Aug;180(2):720
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Urachus / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554640.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Hayashi T, Ujike T, Yamamoto Y, Kamoto A, Nin M, Nishimura K, Miyoshi S, Kawano K: [Female urethral adenocarcinoma with urinary retention: a case report]. Hinyokika Kiyo; 2009 Jul;55(7):429-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Female urethral adenocarcinoma with urinary retention: a case report].
  • A 57-year-old woman presented with urinary retention.
  • Intravenous pyelography demonstrated the filling defect of bladder.
  • Magnetic resonance imaging revealed the mass that had invaded bladder neck at dorsal side of urethra.
  • Pathological examination of transvaginal needle biopsy suggested well-differentiated adenocarcinoma.
  • Pathological diagnosis was urethral adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Urethral Neoplasms / complications. Urinary Retention / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673433.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


96. Ozcanli H, Ozdemir H, Ozenci AM, Söyüncü Y, Aydin AT: [Metastatic tumors of the hand in three cases]. Acta Orthop Traumatol Turc; 2005;39(5):445-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastases developed in the thumb and the big toe, metacarpal bone, and the nail bed following treatment for primary tumors of the bladder, colon, and chondrosarcoma of the proximal femur, respectively.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bone Neoplasms / diagnosis. Hand
  • [MeSH-minor] Adult. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531705.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 25
  •  go-up   go-down


97. Rieder JM, Parsons JK, Gearhart JP, Schoenberg M: Primary squamous cell carcinoma in unreconstructed exstrophic bladder. Urology; 2006 Jan;67(1):199
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma in unreconstructed exstrophic bladder.
  • Bladder exstrophy is associated with an increased incidence of primary adenocarcinoma of the bladder.
  • We report a rare case of squamous cell carcinoma occurring in the unreconstructed, exstrophic bladder of a 53-year-old woman treated with radical cystectomy and radiochemotherapy.
  • This case represents the oldest patient to present with squamous cell carcinoma of an unreconstructed exstrophic bladder.
  • We discuss the potential mechanisms of carcinogenesis in this patient, noting how they may potentially differ from those in a patient with a reconstructed bladder.
  • [MeSH-major] Bladder Exstrophy / complications. Carcinoma, Squamous Cell / complications. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413365.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Romero Otero J, Duarte Ojeda JM, Cruceyra Betriu G, Pérez-Martín ME, Sanchís Bonet A, Tejido Sánchez A, Leiva Galvis O: [Primary adenocarcinoma of the urinary bladder: our experience]. Actas Urol Esp; 2005 Mar;29(3):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the urinary bladder: our experience].
  • [Transliterated title] Adenocarcinoma vesical primario: nuestra experiencia.
  • Adenocarcinoma of the bladder is an uncommon neoplasm.
  • Generally it grows to the density of the wall, so its clinical appearence is delayed, with the subsequent delayed diagnosis and although an agressive treatment is performed, it frequently has a very bad prognosis.
  • Since there are very few publications of this kind of neoplasm in the literature the lines of actuation in this pathology are not well established.
  • We report the eleven cases of adenocarcinoma neoplasm of the bladder treated in our centre and review the literature.
  • [MeSH-major] Adenocarcinoma
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15945250.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 19
  •  go-up   go-down


99. Sugita H, Egami H, Yokoyama Y, Suyama K, Ogawa M: Combined radical retropubic prostatectomy and abdominoperineal excision of the rectum for locally invasive rectal cancer as a less invasive surgery: report of a case. Int Surg; 2007 Sep-Oct;92(5):249-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined radical retropubic prostatectomy and abdominoperineal excision of the rectum for locally invasive rectal cancer as a less invasive surgery: report of a case.
  • The optimal therapy for carcinoma of the rectum with invasion of the prostate gland has not been established.
  • For a patient who has rectal carcinoma invading into the prostate and seminal vesicles and not invading into any other pelvic viscera, we performed combined radical retropubic prostatectomy and abdominoperineal excision of the rectum with reconstruction of the urinary tract by anastomosis of the ureter to the bladder.
  • After the operation, the patient had an infection of the abdominal wound and leakage of the anastomosis of the urethra to the bladder.
  • This technique obviates the need for urinary diversion or urinary reconstruction such as the neobladder in the case of total pelvic exenteration.
  • We consider this procedure is of benefit for improving the quality of life of patients with rectal cancer invading into the prostate.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy. Prostatectomy. Prostatic Neoplasms / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Humans. Male. Neoplasm Invasiveness. Rectum / surgery. Seminal Vesicles / pathology. Seminal Vesicles / surgery. Urethra / surgery. Urinary Bladder / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399094.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


100. Lughezzani G, Sun M, Jeldres C, Alasker A, Budäus L, Shariat SF, Latour M, Widmer H, Duclos A, Jolivet-Tremblay M, Montorsi F, Perrotte P, Karakiewicz PI: Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology; 2010 Feb;75(2):376-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality.
  • OBJECTIVES: To compare stage at radical cystectomy (RC) and cancer-specific mortality (CSM) after RC between non-urachal adenocarcinoma (ADK) and urothelial carcinoma (UC) of the urinary bladder.
  • After adjustment for all covariates, including stage and grade, ADK was not associated with worse prognosis than UC (hazard ratio, 1.05; P = .6).
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / pathology. Cystectomy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Elsevier Inc.
  • (PMID = 20022091.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement